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ABSTRACT 
 
 
The objectives of the study were to investigate and develop lipid and polymeric 
carriers for nucleic acid delivery. These included: i) to develop novel cationic lipids for 
plasmid, oligonucleotide, and siRNA delivery; ii) to develop a novel polymeric delivery 
system, polyethylene glycol (PEG) based bio-conjugate, for oligonucleotide delivery; iii) 
to develop a novel bio-conjugate delivery system for siRNA delivery. 
 
In Chapter 2, we discussed the barriers and strategies of nucleic acid delivery, as 
well as summarized the commonly used lipids, polymers, and the corresponding carriers 
in terms of their characteristics, applications, advantages and limitations. 
 
Cationic lipids are most commonly used transfection reagents in delivery of 
nucleic acids to target cells in vitro. In Chapter 3, we synthesized a series of pyridinium 
lipids which contain a heterocyclic ring and a nitrogen atom. The structure-activity 
relationship (SAR) and formulation of corresponding cationic liposomes were studied for 
gene and siRNA delivery. The pyridinium lipids were mixed with a co-lipid, such as 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) and cholesterol, to prepare cationic 
liposomes by sonication. These liposomes were mixed with plasmid DNA and transfected 
into CHO cells. Several factors including hydrophobic anchor chain length, anchor chain 
type, configuration of double bond, linker type, co-lipid type, cationic lipid/co-lipid 
molar ratio, charge ratio (N/P), concentration of serum, and cell type had significant 
influence on transfection efficiency and cytotoxicity. Pyridinium lipids with amide linker 
showed higher transfection efficiency compared to their ester counterparts. Liposomes 
prepared at a 1:1 molar ratio of pyridinium lipid and co-lipid showed higher transfection 
efficiency. Pyridinium lipids based on a hydrophobic anchor chain length of 16 showed 
higher transfection efficiency and lower cytotoxicity. The trans-isomers of pyridinium 
lipids showed higher transfection efficiency than the cis-isomers at the same fatty acid 
chain length. In the presence of serum, C16:0 and Lipofectamine significantly decreased 
their transfection efficiencies, which were completely lost at a serum concentration of  
30% and higher, while C16:1 trans-isomer still had high transfection efficiency under 
these conditions. The optimized formulation was further investigated in delivery of 
siRNAs and showed equal or higher gene silencing effect at the low dose of siRNAs 
compared to Lipofectamine 2000.  
 
To avoid use of polycations, in Chapter 4, we conjugated galactosylated 
poly(ethylene glycol) (Gal-PEG) to ODN via an acid labile ester linkage of β-
thiopropionate. The conjugate was purified by RP-HPLC and verified by polyacrylamide 
gel electrophoresis. To determine the biodistribution and pharmacokinetic parameters of 
Gal-PEG-ODN, ODN was radiolabeled by 33P before the conjugation reaction. Following 
tail vein injection into rats, Gal-PEG-33P-ODN rapidly cleared from circulation and  
60.2% of the injected dose accumulated in the liver at 30 min post-injection, which was 
significantly higher than that deposited after injection of 33P-ODN. The plasma 
concentration versus time profile of Gal-PEG-33P-ODN was biphasic, with 4.38 ± 0.36 
min as t1/2 of distribution and 118.61 ± 22.06 min as t1/2 of elimination. Prior 
vi 
 
administration of excess Gal-BSA decreased the hepatic uptake of Gal-PEG-33P-ODN 
from 60.2% to 35.9%, suggesting galactose triggers the asialoglycoprotein receptor-
mediated endocytosis of Gal-PEG-33P-ODN by hepatocytes. A large proportion of the 
injected Gal-PEG-33P-ODN was taken up by the hepatocytes as evidenced by 
determination of radioactivity in the digested liver cells upon liver perfusion and 
separation by centrifugation on a Nycodenz gradient.  
 
Although the potency and specificity of siRNA was demonstrated, so far, siRNA 
has not been successfully used as a clinical therapeutic due to its short circulation time in 
blood stream, non specific tissue or cell targeting, and insufficient intracellular transport. 
In Chapter 5, a similar strategy was used to design siRNA conjugates. To target to 
hepatocytes and hepatic stellate cells, galactose and M6P were used as the ligands 
respectively to synthesize Gal-PEG-siRNA and M6P-PEG-siRNA. In this study the 
cleavable disulfide bond was introduced between siRNA and PEG to ensure siRNA 
dissociation from the conjugate in the reducing environment in cytoplasm. After 
conjugation reaction, the conjugate was purified by ion exchange HPLC and verified by 
gel retardation assay. After treatment with DTT, the conjugated siRNA was disassociated 
from its conjugate and verified by gel retardation assay. To evaluate the gene silencing 
ability of siRNA conjugate, an effective luciferase siRNA sequence was designed and 
conjugated with Gal-PEG and M6P-PEG. Then Gal-PEG-siRNA and M6P-PEG-siRNA 
were transfected with luciferase expression HepG2 cells and rat HSCs respectively. We 
found both conjugates could down-regulate the luciferase gene expression for about 40% 
without any transfection reagents, while the gene down-regulation level reached more 
than 98% with the help of cationic liposomes at the same dose. 
 
In conclusion, we synthesized a series of pyridinium lipids and studied their SAR 
and corresponding liposomal formulations. We found pyridinium lipids showed high 
transfection efficiency and had the potential to be used as transfection reagents in vitro. 
The polymeric conjugate delivery systems, Gal-PEG-ODN, Gal-PEG-siRNA and M6P-
PEG-siRNA were successfully designed and developed. The in vitro and in vivo studies 
showed that the conjugate delivery systems could effectively deliver nucleic acids into 
the target cells, release their cargo, and manipulate the target gene expression. These 
research works strengthened the development of lipid and polymeric carriers as the 
effective nucleic acid delivery systems.  
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CHAPTER 1. GENERAL INTRODUCTION 
 
 
Plasmid DNAs, oligonucleotides (ODNs), and siRNAs are negatively charged 
macromolecules. Although the applications and therapeutic outcomes of these genetic 
molecules are much different, there are some similarities in their physicochemical and 
hydrodynamic properties. They are fairly unstable and have very low cellular uptake 
without transfection reagents. Although cationic liposomes are commonly used 
transfection reagents, their performance has to be improved with respect to the 
transfection ability and cytotoxicity. Cationic lipids or polymers are not suitable for in 
vivo delivery of nucleic acids because of their non-specific binding with plasma proteins 
and other tissues via ionic interaction, leading to systemic toxicity. In contrast, target 
ligand containing polyethylene glycol (PEG) based carriers have better characteristics, 
especially for enhanced circulation time and cell specific delivery of nucleic acids. 
Therefore, we hypothesized that: 
 
(i) Pyridinium lipids can effectively transfect nucleic acids (plasmid DNA and 
siRNA) into cells. 
(ii) Galactosylated oligonulceotides will be efficiently delivered to hepatocytes after 
systemic administration. 
(iii) Gal-PEG (or M6P-PEG) conjugation to siRNAs will enhance their uptake by 
HepG2 cells and HSCs.  
 
We proposed the following specific aims:  
 
AIM I: Can pyridinium lipids effectively transfect nucleic acids into cells? Since 
pyridinium cationic lipids were reported to have high transfection efficiency and low 
cytotoxicity, in Chapter 3, we designed a series of novel pyridinium lipids. Therefore, we 
proposed to determine: 
 
(i) Synthesis and characterization of pyridinium lipids. 
(ii) Physicochemical characterization of pyridinium cationic liposomes and their 
lipoplexes. 
(iii) In vitro transfection and cytotoxicity of pyridinium lipid based lipoplexes and 
siRNA complexes.  
 
AIM II: Can galactosylated oligonulceotides be efficiently delivered to 
hepatocytes after systemic administration? Galactosylated poly L-Lysine (PLL)/ODN 
complexes were reported to specifically deliver ODNs to hepatocytes. To avoid non-
specific binding with plasma proteins, in Chapter 4, we designed a non-cationic 
oligonucleotide conjugate. Therefore, we proposed to determine: 
 
(i) Conjugation and purification of Gal-PEG-ODN. 
(ii) In vitro characterization of Gal-PEG-ODN. 
(iii) In vivo biodistribution and pharmacokinetic profiles of Gal-PEG-ODN. 
 
2 
 
AIM III: Can Gal-PEG (or M6P-PEG) conjugation to siRNAs enhance their 
uptake by HepG2 cells and HSCs. Cationic lipid or cationic polymer/siRNA complexes 
can significantly enhance siRNAs’ cellular uptake, but their positive surface may induce 
complement system activation and cytotoxicity. To specifically deliver siRNAs to hepatic 
cells, we designed PEG based siRNA conjugates. Therefore, we proposed to determine: 
 
(i) Conjugation and purification of Gal-PEG-siRNA and M6P-PEG-siRNA. 
(ii) In vitro characterization of Gal-PEG-siRNA and M6P-PEG-siRNA. 
(iii) In vitro gene silencing effects of Gal-PEG-siRNA and M6P-PEG-siRNA. 
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CHAPTER 2. LIPID AND POLYMERIC CARRIER MEDIATED NUCLEIC 
ACID DELIVERY 
 
 
2.1 INTRODUCTION 
 
Gene therapy is defined as the insertion of genes into cells to replace, correct or 
makeup the defective genes for treating acquired and genetic disorders. Gene therapy can 
help us target the origin of the disorder instead of using drugs to alleviate symptoms. In 
the last decade, the spectrum of functional genetic materials used in gene therapy was 
dramatically broadened and diversified. Notably, gene therapy caught the world’s eyes 
again when the two Nobel Prize Laureates, Andrew Fire and Craig Mello, demonstrated 
the mechanism and application of RNA interfering (RNAi) (1,2) in 2006. This is inspite 
of the fact that accidental deaths of virus based genetic therapeutics occurred during 
clinical trials and frustrated enthusiastic scientists all over the world. RNAi which was 
first observed in plants (3), is recognized as a naturally occurring process by which cells 
can regulate gene expression. RNAi molecules typically refer to double-stranded RNA 
(dsRNA) (2), small interfering RNA (siRNA) (19-23 base-pairs) (4), short hairpin RNA 
(shRNA) (5) and micro RNA (miRNA) (6). Although they are structurally different, all 
of them could induce the sequence specific gene silencing by either degradation or 
inhibition of the target mRNA via perfect or mismatched binding in the presence of 
RNA-induced silencing complex (RISC).  
 
Plasmid DNA, oligonucleotide (ODN), and siRNA are the most commonly 
investigated nucleic acids for gene therapy. The applications and therapeutic outcomes of 
genetic molecules may vary depending on their mechanisms in the gene expression 
pathway. They manipulate not only genomic DNA at the transcriptional level, but also 
mRNA and protein synthesis at the post-transcriptional level. Antisense oligonucleotides 
and siRNAs have undergone for clinical trials (7). These molecules are typically 
macromolecules with big hydrodynamic size and negative charge in aqueous solution. 
Naturally occurring genetic molecules are usually fragile and easily degraded by endo- 
and exonucleases. Harsh environmental factors including heat, oxidants, acids, and alkali 
can also cause damage in their structures. 
 
 
2.2 BARRIERS TO NUCLEIC ACID THERAPEUTICS 
 
It is extremely difficult to achieve the expected biological effects of nucleic acids 
by traditional delivery strategies due to many biological barriers. Besides instability, 
several obstacles have to be surpassed before these genetic molecules take action at the 
desired sites. First of all, these macromolecules should go across the biological barriers 
including extracellular, cellular and intracellular biological membranes. For the systemic 
administration of plasmid DNAs or ODNs, the molecules have to go sequentially across 
the vasculature wall, intercellular tissue junction, and cytoplasm membrane of the target 
cells, escape from endosome, and then enter the nucleus. For the systemic administration 
of siRNAs or miRNAs, these molecules should also overcome most of these biological 
4 
 
barriers except nuclear membrane. For local administration, one or two more biological 
barriers may be involved. If the target site is located in central nervous system (CNS), the 
tight junctions between endothelial cells of CNS vessels, the so called Blood Brain 
Barrier (BBB) have to be surpassed. Second, various enzymes and proteins are involved 
in nucleic acid delivery process, which may degrade nucleic acids or trigger immune 
system. Unmodified siRNAs have been reported to be unstable in the presence of high 
concentration of FBS (8). The conserved sequence of nucleic acids could be recognized 
and bound by immune molecules and engulfed by the immune cells or activate the 
complement system (9,10). In some cases the therapeutic effects became negligible or 
null after multiple administrations of genetic materials (11). Third, the low efficacies 
caused by non-specific biodistribution always come along with in vivo studies. Kidney 
plays an important role in the disposition of these macromolecules post systemic 
administration. In general, macromolecules with the molecular weight of less than 50,000 
Da are susceptible to glomerular filtration (12). Cy3 labeled siRNAs were predominantly 
accumulated in the kidney, whereas no accumulation was detected in other organs in 20 
min post i.v. injection (13). The macromolecules that are too large to go through the 
glomerular pore will likely accumulate in the liver because of its loose structure in the 
endothelium and high blood perfusion (12). However, hydrodynamic injection could 
accumulate macromolecules in the highly perfused internal organs, e.g. the liver, 
regardless of their molecular size (14,15). 
 
Considering these barriers (Figure 2.1), a successful in vivo delivery strategy 
should be designed to satisfy the following major criteria: (i) the method should protect 
the genetic molecules from degradation by nucleases; (ii) it should help the genetic 
molecules cross the cell membrane, escape from endosome, and finally enter either 
nucleus or cytoplasm depending on their mechanisms; (iii) it should have no or less side 
effects caused by either genetic molecules or the method itself; (iv) it should prolong the 
circulation time and prevent non specific disposition of genetic molecules to facilitate 
their delivery to the target cells. For the in vitro delivery, the first three criteria have to be 
satisfied.  
 
Current strategies include physical approaches and design of delivery systems. 
Temporary destabilization of cell membrane by a physical force can facilitate the 
intracellular gene transfer, which includes needle injection (16), coated microneedle (17), 
electroporation (18,19), gene gun (20), ultrasound (21), and hydrodynamic delivery 
(14,15). 
 
The nucleic acid delivery systems can be generally classified to two categories, 
viral vectors versus nonviral vectors. Viral vectors exhibited high efficiency at delivering 
both DNAs and RNAs to numerous cell lines and in some cases gave long-term gene 
expression after once administration because of their infection and self replication 
potency. However, the safety issues such as immunogenicity and insertion mutagenesis, 
and manufacturing issues such as the limitation in the size of the inserted DNA fragments 
and difficulty in the scale-up procedures of commonly used viral vectors, are the serious 
problems and have caused wide public concerns (7,9). In contrast, nonviral vectors, 
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Figure 2.1 The barriers and strategies of nucleic acid delivery. 
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including cationic liposomes (lipids), cationic polymers, cationic proteins (peptides), 
dendrimers, non-cationic polymers, nanoparticles, and bioconjugates, are usually safe and 
ease in manufacture. Although significant progress has been made in the design and 
applications of various nonviral delivery systems, the efficiency of nonviral approaches 
are still much less compared to viral vectors. In this article we are going to briefly discuss 
the most popularly used nonviral carriers and their components including lipids and 
polymers in terms of their characteristics, applications, advantages and limitations. 
 
 
2.3 CATIONIC LIPIDS 
 
Cationic lipids are the most commonly used materials for nucleic acid delivery. 
Significant progress has been made in the design and functionalization of cationic lipids 
since the introduction of N-[1-(2,3-dioleoyloxy)propel]-N,N,N-trimethylammonium 
(DOTMA) (22). DOTMA contains a quaternary ammonium group which can condense 
nucleic acids via electrostatic interaction to form a nano-sized particle, and two oleoyl 
chains which facilitate the formation of liposomes and fusion with cell membrane. Other 
most commonly used cationic lipids for nucleic acid delivery include 2,3-dioleyloxy-N-
[2-spermine carboxamide] ethyl-N,N-dimethyl-1-propanammonium trifluoroacetate 
(DOSPA, Lipofectamine); 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP); N-[1-
(2,3-dimyristyloxy) propyl]-N,N-dimethyl-N-(2-hydroxyethyl) ammonium bromide 
(DMRIE), 3-β-[N-(N,N’-dimethylaminoethane) carbamoyl] cholesterol (DC-Chol) (23); 
dioctadecyl amidoglyceryl spermine (DOGS, Transfectam); and 
imethyldioctadecylammonium bromide (DDAB) (24-28). A few such lipids have also 
been tested in initial clinical studies. However, many of the cationic lipids used in early 
clinical trials such as DC-Chol, DMRIE, and GL-67, although effective in vitro, have 
proven inefficient in vivo, especially when compared with viral vectors (28,29). Some 
other promising cationic lipids have also been extensively studied. For example, various 
types of pyridinium lipids containing one or more pyridinium cationic head groups which 
were designed by Mahato’s (30) and other groups (31,32), showed high transfection 
efficiency and low cytotoxicity even at the high concentration of serum in the 
transfection medium (30) (Figure 2.2).  
 
Although the reported cationic lipids are structurally different, most of them 
contain three basic components, the cationic polar head group, the hydrophobic domain, 
and the linker connecting the polar group with hydrophobic group (Table 2.1). Since the 
three parts of a cationic lipid significantly influence the transfection efficiency and 
cytotoxicity of the lipoplexes formed by cationic lipids (liposomes) and nucleic acids, 
understanding these structural parameters is essential for the rational design of efficient 
cationic lipid-based transfection reagents. 
 
 
2.3.1 Cationic Head Group 
 
The positively charged hydrophilic head group of cationic lipids usually consists 
of monoamine group including tertiary amine or quaternary amine, polyamine group,  
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Figure 2.2 Influence of serum on transfection of CHO cells by pyridinium 
liposomes. 
Lipids 5 (C16:0, amide linker) and 7 (C16:1, amide linker, trans-isomer) were used to 
prepare cationic liposomes with co-lipid cholesterol and DOPE at the molar ratio of 1:1. 
Lipoplexes were formed by mixing with luciferase plasmid at the charge ratio of 3:1  
(+/-). Luciferase gene expression in CHO cells was determined at 48 h after transfection. 
The dose of pcDNA3-Luc plasmid was 0.2 µg/well for 4 × 104 cells. D: DOPE. CH: 
cholesterol. 
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Table 2.1 The structures of commonly used cationic lipids. 
 
 
 
Name Cationic head Linker Hydrophobic anchor chain Structural components 
DOTMA 
 
    Monoamine, ether linker, two unsaturated fatty acid chains 
DOTAP 
 
    Monoamine, ester linker, two unsaturated fatty acid chains 
DC-
Cholesterol 
 
    Monoamine, carbamate linker, cholesterol 
Pyridinium 
lipid 
 
    Pyridinium ring, amid linker, unsaturated  fatty acid chains 
SAINT 2     Pyridinium ring, aliphatic linker, two unsaturated fatty acid chains 
DOGS      
Polyamine, amid linker, two saturated fatty 
acid chains 
DOSPA     Polyamine, ether linker, two unsaturated fatty acid chains 
BGSC      Polyamine, carbamate linker, cholesterol 
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amidinium group, or guanidinium group (such as bis-guanidiniumspermidine-cholesterol 
(BGSC)) (33). Recently, various heterocyclic cationic lipids have been studied and used 
for nucleic acid delivery. Pyridinium heterocyclic ring in the cationic amphiphile, first 
introduced in the 1940s, has been shown to have antiseptic and antibiotic properties. A 
series of pyridinium lipids have been developed, and some of them have been reported to 
reach or surpass the performance of commercially available transfection reagents both in 
vitro and in vivo (30,31,34). In addition to pyridinium cationic lipids, other types of 
heterocylic head groups have also been investigated in the design of cationic lipids, such 
as imidazole, piperizine, and amino acid (35,36). The main function of cationic head 
groups is to interact with negatively charged DNA or RNA molecules via electrostatic 
interaction to form the slight positively charged condensed particles, leading to enhanced 
cellular uptake (37) and endosomal escape (38). 
 
 
2.3.2 Hydrophobic Lipid Anchor Group 
 
The hydrophobic domains usually contain either simple aliphatic hydrocarbon 
chains such as fatty acid chains of various lengths and unsaturation states, or steroids 
such as cholesterol, which helps in forming liposomes and exchanging lipids of cell 
membrane (12). Previous studies suggested that the type and length of aliphatic chain 
influenced the transfection efficiency (30). Most effective cationic lipids have two linear 
fatty acid chains such as DOTMA, DOTAP and SAINT-2. In general, cationic lipids 
containing one hydrocarbon chain and more than two hydrophobic chains might cause 
either toxic or poor transfection (39,40) although tetraalkyl lipid chain surfactants, the 
dimer of N,N-Dioleyl-N,Ndimethylammonium chloride (DODAC), has shown enhanced 
gene transfer over DODAC (41).  
 
The degree of unsaturation and configuration of the hydrophobic chain also 
influence the transfection efficiency and cytotoxicity (31). The degree of unsaturation in 
the lipid structure affected the fusogenicity of the lipid (Lα to HII transition) (42,43). The 
double bond in the fatty acid chain decreased the phase transition temperature of the 
lipids (30). The decrease in phase transition temperature increased fusogenicity, leading 
to an increase in transfection efficiency (44). To investigate the relevance of 
configuration of double bond and cationic lipids’ performance, we synthesized new 
pyridinium cationic lipids with one double bond (cis or trans) in the hydrophobic carbon 
chain. All the trans-oriented lipids regardless of their hydrophobic chain lengths (C16:1, 
C18:1, and C20:1) enhanced the transfection efficiency compared to their cis-oriented 
counterparts (30) (Figure 2.3). This trend was in good agreement with the previous report 
by Van der Woude et al. (31). The influence of aliphatic chain length on the performance 
of cationic lipids was a little bit complicated in the reported studies. Felgner et al. 
reported that the transfection efficiency increased with the decrease in the hydrophobic 
chain length from C18 to C14 in the DOTMA derivatives (45). In the study of pyridinium 
cationic lipids, we found that the unsaturated lipid C16:1 had better transfection effect 
compared to C18:1 and C20:1 (30,34). A similar trend was also found in DOTAP 
derivatives (35). However, it was found that transfection efficiencies were higher for the 
lipids with longer alkyl chain (C18 > C16 > C14 > C12) in the study of trilysine-based  
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Figure 2.3 Influence of configuration (cis vs. trans) of pyridinium lipids on 
transfection efficiency. 
Lipids 6 (C16:1, amide linker, cis-isomer), 7 (C16:1, amide linker, trans-isomer), 9 
(C18:1, amide linker, cis-isomer), 10 (C18:1, amide linker, trans-isomer), 11 (C20:1, 
amide linker, cis-isomer) and 12 (C20:1, amide linker, trans-isomer) were used to prepare 
cationic liposomes with DOPE at the molar ratio of 1:1. Lipoplexes were formed by 
mixing with luciferase plasmid at the charge ratio of 3:1 (+/-). Luciferase gene expression 
in CHO cells was determined at 48 h after transfection. The dose of pcDNA3-Luc 
plasmid was 0.2 µg/well for 4 × 104 cells. D: DOPE. 
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Gemini surfactants with є,є-linkage (46). Takahashi et al. also reported the 
polyamidoamine (PAMAM) dendron-bearing lipids with longer alkyl chain length 
showed higher transfection efficiency compared to their short chain counterparts (47). 
The conflict facts with respect to hydrophobic chain length indicated that the transfection 
ability of cationic lipids is strongly determined by both cationic head group and its 
compatible hydrophobic lipid anchor length. A hypothesis based on “dimensionless 
packing parameter, P = V/a•l” (48,49) may explain why these experimental data showed 
conflict.  Here, “V” denotes the hydrophobic chain volume, “a” the optimal cross-
sectional head group area and “l” the length of the hydrophobic tails. When ½ < P ≤ 1, 
the DNA/cationic liposomes complexes will undergo lamellar organization, Lα ; while 
when P > 1,  the complexes will prefer inverted structures, HII. Lα phase was more stable 
and resulted in a lower transfection potential compared to HII phase which had a higher-
order inverted hexagonal structure and was believed to have the ability to fusion with 
plasma membrane and trigger the endosomal escape resulting in higher transfection 
efficiency (50,51). 
 
 
2.3.3 Linker Group 
 
Stability, biodegradability, and transfection efficiency of a cationic lipid greatly 
depend on the structure of the linker that binds the polar head to the hydrophobic anchor 
chains (52). Most commonly used linkers include ethers, esters, amides, or carbamates. 
Ether linker was reported to be stable and non-biodegradable when used as the linkage in 
cationic lipids. An enhanced gene transfection of cholesterol-based cationic lipids was 
observed when ether was used as the linker compared to those of the lipids based on 
either ester or urethane linkers (53). Both esters and amides are biodegradable linkages 
and shown high transfection efficiency in pyridinium cationic lipids (32). However, 
pyridinium cationic lipids with amides linkage were reported to be chemically stable with 
higher melting point but lower phase transition temperature, resulting in higher 
transfection efficiency compared to their ester-bond counterparts (30) (Figure 2.4); in 
contrast esters were not stable chemically, but showed less toxic (54). Carbamate group 
structurally shares the properties of both ester and amide and showed high transfection 
efficiency and low toxicity when used as the linker in DC-Chol (27) and BGSC (33). 
Since cleavable lipids have low cytotoxicity and could facilitate nucleic acid release from 
lipoplexes after cleavage, the design of new types of linkages are of interest, such as 
photo-sensitive (55), pH-sensitive (56), and redox-sensitive linkages (57). 
 
Although the above three basic components of cationic lipids have been studied 
extensively, it should be mentioned that the performance of a cationic lipid in the nucleic 
acid delivery is contributed by the entire molecule rather than the three independent parts. 
In summary, transfection efficiency of cationic lipids greatly depends on (i) the extent of 
DNA or RNA condensation, (ii) enhanced cellular uptake due to ionic and/or 
hydrophobic interaction with negatively charged biological surfaces, and (iii) membrane 
fusion via transient membrane destabilization to achieve delivery into the cytoplasm 
while avoiding degradation in the lysosomal compartment. However, for siRNAs, the  
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Figure 2.4 Influence of linker type (ester vs. amide) of pyridinium lipids on GFP 
(A) and luciferase (B) plasmids transfection. 
(A) C16:0 lipid with amide linker and C16:0 lipid with ester linker were used to prepare 
cationic liposomes with co-lipid DOPE and cholesterol at the molar ratio of 1:1. 
Lipoplexes were formed by mixing with GFP plasmid at the charge ratio of 3:1 (+/-). 
GFP gene expression in CHO cells was observed at 48 h after transfection using 
fluorescence microscopy. The dose of pCMS-EGFP plasmid was 0.4 µg/well for 4 × 104 
cells. (B) lipids with easter linker and lipids with amide linker were used to prepare 
cationic liposomes with DOPE at the molar ratio of 1:1. Lipoplexes were formed by 
mixing with luciferase plasmid at the charge ratio of 3:1 (+/-). Luciferase gene expression 
in CHO cells was determined at 48 h after transfection. The dose of pcDNA3-Luc 
plasmid was 0.2 µg/well for 4 × 104 cells. 
  
C16:0, amide linker
C16:0, ester linker
DOPE CholesterolCo-lipid type
(A)
Ester linker Amide linker
0
100000
200000
300000
400000
500000
600000
C
14
:0
C
16
:0
C
18
:0
C
14
:0
C
16
:0
C
18
:0
L
ip
of
ec
ta
m
in
e
C
on
tr
ol
L
uc
ife
ra
se
 (R
L
U
/μg
 p
ro
te
in
)
(B)
13 
 
complete condensation may not be achieved easily and the stability of siRNA/lipid 
complexes is relatively low compared to that of plasmid DNA/lipid complexes (58). In 
this condition, other mechanisms such as temporary destabilization or pore forming of 
cell membrane may play the key role in siRNA transfer.  
 
 
2.4 CATIONIC POLYMERS 
 
Cationic polymers are also commonly used for the nucleic acid delivery. Cationic 
polymers readily form complexes with nucleic acids via electrostatic interactions and 
create a net positive charge under appropriate conditions. This facilitates cell attachment, 
subsequent internalization by endocytosis or membrane fusion, and endosomal escape by 
proton sponge (59). The structures of the cationic polymers are much different. These 
include linear polymers such as chitosan and linear poly(ethyleneimine) (LPEI), branched 
polymers such as branched poly(ethyleneimine) (BPEI), circle-like polymers such as 
cyclodextrin, net-work (cross-linked) type polymers such as cross-linked poly(amino acid) 
(PAA), and dendrimers (Figure 2.5). To overcome the cytotoxicity of cationic polymers, 
the biodegradable polymers were designed, e.g. poly(4-hydroxy-L-proline ester) (PHP), 
poly(amino-ester), PAA. The design of the new functional polymers has become a hot 
area in formulation and drug delivery. To understand the properties and application of 
these polymers in nucleic acid delivery, in the following section we reviewed the mostly 
used cationic polymers.  
 
 
2.4.1 Polyethylenimine (PEI) 
 
Polyethylenimine is one of the most widely used synthetic carriers for nucleic 
acid delivery (59). Based on its structure, PEI exists as either linear PEI or branched PEI. 
PEI is a highly positively charged polymer. Linear PEI contains all secondary amines in 
its backbone except the terminal groups. In contrast, branched PEI contains primary, 
secondary and tertiary amino groups at the estimated ratio of 1:1:1 (60). The different 
types of amine groups have different pKa values and could be protonated in different 
levels at the given pH. This confers PEI a superior buffering capacity over a wide range 
of pH during the effective delivery of its cargoes into the target cells via endocytosis 
pathway. After endocytosis, unprotonated amines would be protonated at acidic pH in 
endosome, and this increases the influx of protons, chloride ions and water into the 
endosomes. The increased osmotic pressure causes endosome to swell and rupture, by 
which the endosomal content is released (59,61). This is widely accepted “proton sponge” 
hypothesis (62,63). PEI’s buffering capacity may protect its cargoes from degradation 
and lead to early endosomal escape during the endosomes’ maturation process and their 
subsequent fusion with the lysosome. The transfection efficiency and cytotoxicity of PEI 
strongly depend on its molecular weight. Increase in its molecular weight results in the 
increase of its transfection efficiency as well as its cytotoxicity, mainly necrosis probably 
caused by strong aggregation (64) and adherence on cell membrane (65). Serveral studies 
have done to determine the effect of PEI molecular weight on transfection efficiency (66-
68). It was believed that the most suitable molecular weight of PEI for complexation  
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Figure 2.5 The structures of commonly used cationic polymers. 
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with DNA segments was between 5 and 25 kDa (68), although some groups reported that 
high (800 kDa) (64) and low (2 kDa) (67) molecular weight PEIs also showed good 
transfection at their preferring N/P ratios.  
 
In addition to the effect of molecular weights, the different behaviors were found 
between branched PEI and linear PEI. Branched PEI has relatively higher DNA 
condensing capacity compared to linear PEI. Kircheis et al. found that the DNA 
complexes formed by 25 kDa branched PEI was about 180 nm while the complexes 
formed by 22 kDa linear PEI aggregated at the same N/P ratio and ionic strength (69). It 
was also reported that high content of primary amines made PEI polyplexes more stable 
(70). Based on these studies, branched PEI is more effective than linear PEI in the in vitro 
transfection. However, stronger association with the bound nucleic acids might cause the 
difficulty to de-assemble and release its cargoes after endosomal escape (38). In contrast, 
linear PEI has relatively lower condensation capability as well as its kinetic instability 
under salt conditions (71), resulting in the more efficient dissociation. Linear PEI is less 
cytotoxic than its branched counterparts (71). These characteristics make linear PEI more 
effective in the in vivo delivery (71-73). Although both branched and linear PEI were 
widely used, the nature of PEI still has to be improved to satisfy the safety and 
effectiveness requirements of in vivo nucleic acid delivery (74). Recently, more and more 
studies have been focused on the improvement of PEI’s properties (72,75). 
 
 
2.4.2 Chitosan 
 
Chitosan is produced from the naturally occurring chitin which is the structural 
element in the exoskeleton of crustaceans and cell walls of fungi. Partial deacetylation of 
chitin exposes amine groups of chitosan makes it a cationic polymer. Chitosan is a linear 
polysaccharide polymer, which is composed of D-glucosamine (deacetylated unit) and N-
acetyl-D-glucosamine (acetylated unit) linked with randomly distributed β-(1, 4) 
glycosidic bonds. Biodegradability, biocompatibilities, low immunogenicity, and low 
cytotoxicity render chitosan one of the most prominent carriers for nucleic acid delivery 
(76-78). The size and zeta potential, morphology, stability, and biological effect of its 
polyplexes, are strongly dependent on chitosan’s molecular weight, degree of 
deacetylation, N/P ratio and pH (79,80). Increase in molecular weight of chitosan 
increased the size of polyplexes, resulting in the increase of transfection efficiency 
(81,82). 
 
MacLaughlin et al. studied the wide range molecular weight chitosans from 7 to 
540 kDa and found that the particle size of chitosan/DNA complexes prepared at the N/P 
ratio of 6:1 with a plasmid concentration of 100 μg/mL significantly increased from 100 
nm to 500 nm along with the increase of chitosan’s molecular weight (82). A similar 
trend was found by Katas et al. when they used chitosan hydrochloride to condense 
siRNAs (78). Huang et al. also reported that low molecular weight chitosan was less 
efficient in condensing plasmid DNA and corresponding polyplexes were less stable 
during dilution compared to its high molecular weight counterparts (83). This may be 
because the high molecular weight chitosan interacts with DNA molecules by not only 
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via electrostatic interaction but also via effective chain entanglement (84). However, in 
some cases high molecular weight could not guarantee high gene transfection and 
silencing since the strong interaction force inside polyplexes might hinder the release of 
loaded nucleic acids (85,86). These facts emphasized the importance of a fine balance 
between extracellular protection and intracellular release to obtain expected biological 
effects. Since the positive charge of chitosan comes from deacetylation, the degree of 
deacetylation is important for nucleic acid delivery. The commonly used chitosans are 
highly deacetylated, probably 80% or above (77,78,82), to expose more charge for 
condensing nucleic acids. Low deacetylation caused low transfection efficiency (83), 
although the similar condensation effect as high degree of deacetylation could be 
achieved at a relatively high N/P ratio. Liu et al. studied chitosan’s protonation and its 
complexation with DNA at different pHs and found that amine groups were almost 
completely protonated at the pH below its pKa (about 6.5), resulting in the increased 
electrostatic interaction between chitosan and DNA (87). In contrast, the amine groups 
were hardly protonated at the pH above 7.5, resulting in poor DNA condensation (88). 
However, the low transfection efficiency was observed at the pH below 6.5, due to the 
hindrance of endosomal escape and cargo release, although chitosan could be highly 
protonated (88). In addition to charge density, other characteristics also influence the 
performance of chitosan, including solubility (89), degradation (90), and crystallinity (91). 
The proper modification of chitosan with other polymers or ligands could improve its 
performance in the delivery of nucleic acids.  
 
 
2.4.3 Cyclodextrin (CD)-based Cationic Polymers 
 
Cyclodextrins are a naturally occurring cyclic oligosaccharides constituted by 6-8 
(+) glucopyranoside units, linked by α-1,4-linkages, and well known as α-, β-, or γ-CD, 
respectively. They are topologically represented as torus-like macro-rings with the 
relatively hydrophobic inner cavities, where various molecules can be encapsulated and 
form supramolecular inclusion complexes (92). Therefore, CDs and their derivatives have 
been extensively studied for understanding the mechanism of molecular recognition and 
as drug carriers to enhance the solubilization, stabilization and absorption (93). Since 
nucleic acids are negatively charged hydrophilic macromolecules, they cannot be trapped 
into native CD’s cavities like small molecules. To use CDs for nucleic acid delivery, they 
have to be incorporated by cations or modified by other cationic polymers. Davis’ group 
developed a linear β-CD containing cationic polymer by polymerization of a bifunctional 
β-CD monomer, (2-aminoethanethio)-β-CD derivative, via the cationic linkages, 
dimethylsuberimidate (94). Another modification was available by conjugating multiple 
oligoethylenimine (OEI) arms onto the α-CD core to form a star-shaped cationic polymer 
(95). These kinds of modifications of CDs were reported to enhance the in vitro 
transfection efficiency and lower the cytotoxicity.  
 
The most important feature of CD-containing polymers is their capability to form 
the inclusion complexes which can be used as the functional moieties for further 
modifications. Grafting PEG-adamantane on the β-CD moieties of DNA polyplexes was 
reported to stabilize polyplexes, decrease cytotoxicity, and enhance transfection 
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efficiency (96). Recently, a new class of cationic supramolecules, CD-based 
polyrotaxanes, had been designed for gene delivery (97,98). The new cationic 
polyrotaxane composed of multiple OEI grafted β-CDs that were threaded on PPO block 
and blocked on the two ends of a Pluronic (PEO-PPO-PEO) triblock copolymer (99). 
Cationic polyrotaxanes effectively condensed plasmid DNA to nanoparticles and showed 
low cytotoxicity and high transfection efficiency in BHK-21 and MES-SA cells (98). 
 
 
2.4.4 Dendrimers 
 
Dendrimer consists of a central core molecule, from which a number of highly 
branched arms “grow” to form a tree-like structure with a manner of symmetry or 
asymmetry. Dendrimers have unique architecture and properties which make dendritic 
polymers the focus of much research in drug and gene delivery as well as diagnostics and 
bioengineering. Dendritic polymers could be constructed by stepwise synthesis using a 
divergent or convergent method (100). The most popularly used dendrimers are 
Polyamidoamine (PAMAM) and polypropylenimine (PPI) dendrimers. PAMAM 
dendrimers are synthesized commonly starting from a core molecule, ethylenediamine or 
ammonia, then esterizing the core with methylacrylate followed by amidation of the ester 
with ethylenediamine. The resulting polymer after one reaction circle is termed as a 
generation (e.g. G2, G3…). If the reactions terminate just after esterization, the term “half 
generation” (e.g. G2.5, G3.5…) will be given to the dendritic polymer.  
 
For PPI dendrimers, the branched PPI units will grow from the core molecule, 
butylenediamine (DAB), by Michael addition followed by hydrogenation of nitrile 
groups (100). Because of their unique architecture dentrimers adopt a planar-elliptical 
shape or spherical shape depending on the number of generations. Usually the inner 
structure is loose due to the low density of molecules compared to the compact structure 
in the outer layer due to the high density of molecules. The space inside the dendrimer is 
favorable for small molecules to be encapsulated in. However it seems impossible for 
nucleic acids due to their large size. Commonly, the cationic dendrimers with the outside 
positive surface are suitable to condense and carry the negatively charged nucleic acids 
like other cationic polymers. Dendrimer interacts with biological membranes by its pore 
forming ability which may induce the small, transient pores near the contact site. The 
pore forming ability depends on the charge density and the generation of dendrimer. The 
higher the charge density or generation, the higher the transfection efficiency (100). 
However, large dendrimers with the high generations commonly show higher 
cytotoxicity than the dendrimers with low generations (101). In general the toxicity of 
dendrimers is lower than that of PEI, PLL or DEAE-dextran (74). Another important 
aspect of dendrimer is its pH buffering capacity which can cause endosome disruption 
and facilitate the dendrimer/nucleic acid complex release (61). Since dendrimers show 
higher transfection efficiency and low cytotoxicity, dendrimer-based transfection 
reagents have already been commercialized, including PolyFect and SuperFect 
(QIAGEN), Starburst® PAMAM dendrimers (Dendritic Nanotechnologies), Priostar® 
dendrimers (Starpharma), and Astramol™ (DSM).  
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Dendrimers to have similar or superior performance compared to cationic 
polymers or lipids (102,103). However, only about 1% of PAMAM dendrimers (G3 and 
G4) was detected in blood circulation compared to more than 60% of dendrimers 
accumulated in the liver at 1 h after intravenous injection into rats (104). To use 
dendrimers as in vivo delivery system, some improvement has to be made to decrease 
their non specific distribution and increase their efficacies. Conjugation of hydrophilic α-
CD to G2 to G4 PAMAM dendrimers significantly increased their transfection efficiency 
and decreased their cytotoxicity caused by highly dense positive charge even at the high 
N/P ratio (105). Taratula reported that coating of PPI dendrimer (G5) /siRNA 
nanoparticles with PEG-luteinizing hormone-releasing hormone (LHRH) peptide could 
stabilize the siRNA complexes in the presence of plasma. These targeted particles were 
efficiently accumulated in the tumor area compared to non-targeted particles (106). 
Quaternization of primary amino groups especially external amine was also explored in 
high generation of PPI dendrimers to reduce their cytotoxicity (107). However, the 
transfection efficiency might be decreased due to the insufficient surface charge (108). 
 
 
2.5 NON-CATIONIC LIPIDS AND POLYMERS 
 
Non-cationic polymers or lipids cannot condense nucleic acids via electrostatic 
interaction and in most cases they work as the constituents in the cationic vectors. For 
example, DOPE and cholesterol are the two most commonly used neutral co-lipids for 
preparing cationic liposomes. The incorporation of fusogenic lipids such as DOPE can 
improve endosomal escape by membrane fusion between the liposomal and endosomal 
bilayers (109,110). DOPE has been shown to be a major driving force in promoting 
transfection efficiency of SAINT-2 cationic lipids, as it undergoes Lα to HII transition 
when dispersed in a physiological buffer (111). The use of cholesterol as a co-lipid has 
been reported to show enhanced in vivo gene expression, as cholesterol containing 
liposomes could efficiently interact with the cell membrane in the presence of serum 
(112).  
 
Some new materials have been created by conjugating lipids to polymers. 
Branched PEI-cholesterol water soluble lipopolymer was synthesized by Han et al. (113) 
and Wang et al. (114). These branched PEI-cholesterol conjugates self-assemble into 
cationic micelles with diameter of approximately 50 nm in aqueous buffer and showed 
enhanced transgene expression and low cytotoxicity compared to PEI control in CT-26 
colon adenocarcinoma and 293 T human embryonic kidney transformed cells (113,114). 
PEG based non-cationic polymers or lipids are another widely used constituent in the 
cationic liposomal or polymeric carriers. PEGylation of cationic lipids or polymers can 
be done by either surface modification or incorporation of pegylated moieties into 
liposome preparation. PEGylation of Stabilized Plasmid Lipid Particle (SPLP) or Stable 
Nucleic-Acid-Lipid Particle (SNALP) could neutralize the positively charged surface of 
cationic lipids and provide a neutral, hydrophilic coating to the particle's exterior using a 
diffusible PEG-lipid conjugate, PEG2000-C-DMA, resulting in the long circulation time 
and low immune response (115,116). Systemic administration of anti-HBV siRNAs 
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containing pegylated SNALP significantly inhibited HBV DNA and HBsAg expression 
in a HBV mouse model (116).  
 
Besides the above discussion, non-ionic polymers were designed and used 
independently in the nucleic acid delivery. Pluronic®, also called poloxamer, is a series of 
block copolymers based on ethylene oxide and propylene oxide. It is widely used in drug 
and gene delivery (117). Enhanced gene expression was observed post injection of 
plasmid DNA with SP1017 which is the combination of Pluronics L61 and F127 into rats’ 
skeletal muscle compared to another non-ionic polymer, polyvinyl pyrrolidone (PVP) 
(118). Further study showed that SP1017 could improve DNA distribution inside 
muscular tissue resulting in increased bioavailability, although Pluronic did not increase 
the in vitro gene transfection and expression since it interacted with DNA via weak force 
such as hydrogen bonds rather than strong electrostatic interaction (118). Another 
frequently reported non-ionic polymer was poly(lactic-co-glycolic acid) (PLGA) or its 
derivatives, by which nucleic acids could be encapsulated into the core or absorbed on 
the surface of PLGA nanoparticles (119,120).  
 
Bioconjugation technology to deliver oligonulceotides or siRNAs is also being 
widely investigated. Oligonucleotides and siRNAs are easier to be conjugated with lipids 
or polymers since they are relatively small compared to plasmids (121), which can loose 
their supercoiled configuration. Bioconjugation of ODN and siRNA is discussed in the 
following section. 
 
 
2.6 DESIGN ELEMENTS FOR EFFECTIVE NUCLEIC ACID DELIVERY 
 
To achieve efficient delivery of nucleic acids, in general, a delivery system has to 
be designed based on the cargo’s properties and desired therapeutic effect using lipids, 
polymers, or their combination.  
 
 
2.6.1 Liposomal Delivery System 
 
Liposomes, the microscopic bubbles of amphiphilic lipids surrounding an aqueous 
interior, which have a history of roughly 40 years, have been proven to be a unique tool 
for studying both structural and dynamic aspects of natural membranes (122,123). Given 
their biocompatibility, biodegradability, low toxicity and immunogenicity, liposomes 
have attracted attention in the past three decades as pharmaceutical carriers of great 
potential (124). Liposomal delivery system is the most widely used carrier for in vitro 
and in vivo nucleic acid delivery. Although in some cases cationic lipids are used alone, 
most cationic lipids are used to prepare cationic liposomes which contain at least two 
components, the cationic lipid and neutral co-lipid. The selection of co-lipids is important, 
as they can significantly influence the overall performance of cationic liposomes. We 
used DOPE and cholesterol as the co-lipid to prepare pyridinium-lipid based cationic 
liposomes respectively to transfer plasmid DNA in CHO cells and found that both DOPE 
and cholesterol could enhance transgene expression when used with each favorite 
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cationic lipids (30). The cationic lipids are usually considered to be transfection 
inefficient if they cannot work well with co-lipids to improve gene transfection. However, 
Mukherjee et al. proposed a different strategy that involved combination of co-lipids 
(DOPE, cholesterol and DOPC) in equimolar ratio. This approach could improve the 
transfection efficiencies of cationic lipids which had been proven transfection inefficient 
when formulated with each of these co-lipids alone (125). 
 
There is a strong relationship between the morphology of lipoplexes and their 
performance. A few models were introduced to predict and mimic the morphologies of 
lipoplexes, including external model (DNA is adsorbed onto the surface of cationic 
liposomes), internal model (DNA is surrounded by cationic liposomes), beads (cationic 
liposomes) on a string (DNA) model, and globular model (126). It was recently agreed 
that the “phase models” of lipoplexes were more helpful in understanding their 
transfection abilities, including the lamellar structure (Lα), the inverted hexagonal 
structure (HII), and the intercalated hexagonal structure (HI) (126). Many excellent 
research or review papers have been published in terms of these issues (51,111,126,127). 
In general, Lα phase lipoplexes are relatively stable and have low transfection activity, 
while HII phase lipoplexes are instable and show high propensity of lipid fusion resulting 
in high transfection efficiency. Besides liposomal components, the charge ratio (N/P ratio) 
of cationic lipids/nucleic acids, preparation methods, ionic strength, and temperature, 
may also influence the lipoplex formation and its morphology. Charge ratio was one of 
the mostly studied issues and found to significantly influence the morphology of 
lipoplexes and their transfection abilities. At the high N/P ratio, the lipid/DNA complex 
was found to adopt a globular structure with the effective condensation (128), while at 
the low N/P ratio, the beads on a string structure could be formed along with the addition 
of DNAs (129). Highly condensed positively charged particles are easier for cells to take 
up. However, if the concentration of cationic liposomes is too high, it may cause 
cytotoxicity. The size of lipoplexes was also reported to have the influence on 
transfection efficiency. So far the effect of size was controversial since the conflicting 
results were reported in the previous studies. However it was believed that large 
lipoplexes were more efficient to transfect nucleic acids in vitro since large particles led 
to faster sedimentation, the maximum contact with cell membrane, and easier 
dissociation of lipoplexes post endocytosis. In contrast, the small size particle was much 
safer and appropriate for in vivo delivery of nucleic acids (126). 
 
To design an in vivo liposomal delivery system, surface modification of cationic 
liposomes was reported to be effective. Sato et al. successfully used vitamin A-coupled 
cationic liposomes to specifically deliver siRNAs to hepatic stellate cells in fibrotic rats, 
by which they almost completely resolved liver fibrosis and prolonged rats’ lives (130). 
Since PEG chain could sterically stabilize the liposomes and prevent early capturing by 
macrophages, pegylated cationic liposomes were used for in vivo delivery of nucleic 
acids (131-133). Systemic administration of SNALP/APOB-specific siRNAs in 
cynomolgus monkeys could silence APOB mRNA expression more than 90% and this 
effect lasted for 11 days (133). 
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2.6.2 Oligonucleotide and siRNA Conjugates 
 
Since oligonucleotides and siRNAs are readily modified by other functional 
molecules to improve their stability and pharmacokinetic behaviors (134), the 
conjugation reaction was widely used to link nucleic acid with functional lipids (135,136), 
polymers (134,137), and nanoparticles (138). ODN or siRNA can be covalently linked 
with functional molecules via non-degradable or degradable linkage, such as acid-labile 
ester (134,139) and reducible disulfide bond (140,141). Both 3’- and 5’-terminus of 
single strand oligos were used for conjugation (134,142). For siRNAs, however, it was 
known that antisense strand of siRNA worked as the template in RISC for RNAi. It was 
further shown that 5’-terminus of antisense strand is more important than 3’-terminus and 
determines RNAi activity (143-145). Therefore, the 3’- and 5’-end of sense strand are 
preferred for conjugation (121). 
 
Cholesterol is commonly used lipid for ODN and siRNA conjugation. After 
conjugation, the hydrophobicity will be increased resulting in the change of in vivo 
distribution. Cheng et al. conjugated triplex-forming oligonucleotide (TFO) with 
cholesterol at its 3’-terminus via disulfide bond and found that conjugation with 
cholesterol had little effect on the triplex-forming ability of the TFO with target duplex 
DNA and enhanced hepatic uptake of ODNs after i.v. injection into rats (135) (Figure 
2.6A). To make apolipoprotein B (apoB) siRNA conjugate, Soutschek et al. linked 
cholesterol with the phosphorothioated antisense RNA oligo at 3’-terminus via 
aminocaproic acid-pyrrolidine linkage followed by annealing with the complementary 
sense strand oligo. Systemic administration of siRNA-cholesterol resulted in silencing of 
apoB mRNA in liver and jejunum as well as reduction of the total cholesterol level (136). 
Water soluble polymers with the functional terminal groups were alos used to conjugate 
with nucleic acids, such as PEG (134,141) and HPMA (137) (Figure 2.6B). We 
conjugated galactosylated poly (ethylene glycol) (Gal-PEG) to ODN via an acid-labile 
ester linkage of β-thiopropionate. Gal-PEG-ODN was found stable when incubated it 
with rat serum, while the ester linkage was cleaved and ODN dissociated from the 
conjugate when environmental pH was 5.5. Systemic administration of Gal-PEG-ODN 
significantly enhanced cellular uptake of ODNs in hepatocytes since galactose residue is 
the specific ligand for asialoglycoprotein receptors on the surface of hepatocytes, while 
the accumulation of ODNs in liver was significantly inhabited by pre-injection of BAS-
Gal (134) (Figure 2.7).  
 
Pegylated siRNA was studied by Park’s group (141,146) and Katoka’s group. 
(139,147) Like pegylated ODN, pegylation could protect siRNA from nuclease digestion, 
prolong its systemic circulation, and confer targeting effect if a targeting ligand is 
attached to PEG. In Park’s study, N-Succinimidyl 3-(2-pyridyldithio)propionate (SPDP), 
a hetero-functional coupling reagent, was first reacted with NH2 at 3’-terminus of the 
sense strand to produce a 2-pyridyl disulfide activated siRNA which could further react 
with sulfhydryl group in PEG to form a disulfide bond. In their study, the peptides were 
used as ligands, e.g. vascular endothelial growth factor (VEGF) (141) and LHRH (146). 
In contrast, Katoka used acid-labile linkage between siRNA and PEG and lactose residue 
as a ligand (139). Both Park and Katoka reported that pegylated siRNA could  
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Figure 2.6 Conjugation of TFO to cholesterol (A) and HPMA (B). 
(A) Thiocholesterol was reacted with bis-(5-nitro-2-pyridyl)-disulfide in pyridine at room 
temperature for 2 h to form 2-(5’-nitropyridyl)-3-cholesterol disulfide. Then, 2-(5’-
nitropyridyl)-3-cholesterol disulfide was conjugated to TFO-SH in DMF under N2 
protection at 40 °C for 24 h. (B) Poly(HPMA-co-MA-GFLG-ONP) and TFO-NH2 were 
reacted in the presense of N,N′-diisopropylethylamine (DIPEA) in DMSO at room 
temperature, followed by reaction with p-Aminophenyl-6-phospho-α-D-
mannopyranoside (papM6P) in the presense of DIPEA. 
(A)
(B)
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Figure 2.7 Synthesis scheme (A), biodistribution (B), and hepatic localization (C) 
of Gal-PEG-ODN. 
(A) p-Aminophenyl β-D-galactopyranoside reacted with acrylate-PEG-NHS in DMF. 
Then Gal-PEG-acrylate was conjugated to reduced 3′-thiol ODN by Michael addition in 
nuclease free water. (B) Gal-BSA (10 mg/Kg) was injected intravenously into rats 2 
minutes before injection of Gal-PEG-33P-ODN at a dose of 0.2 mg/Kg. At 30 minute post 
injection, rats were sacrificed, major organs were isolated and radioactivity was 
determined. (C) The liver was perfused by collagenase/pronase digestion at 30 min post 
injection of 33P-ODN or Gal-PEG-33P-ODN at a dose of 0.2 mg/Kg. Parenchymal 
(hepatocytes) and non-parenchymal cells were separated and the associated radioactivity 
was measured. 
  
(A)
(B) (C)
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spontaneously form polyelectrolyte complex (PEC) micelles with PEI (148) or pegylated 
polyplexes with poly(L-lysine) (PLL) (147) via electrostatic interaction. After complex 
formation the negatively charged siRNAs would be buried in the core and completely 
covered by hydrophilic PEG shell. This kind of nanoparticles were found to be 
significantly accumulated in the tumor region in an in vitro three-dimensional tumor 
model (147) and tumor bearing mice after systemic administration (148) due to enhanced 
permeability and retention (EPR).  
 
Although siRNA conjugates have been studied recently, it is still too early to see 
their benefits in the clinic. Most of these studies are still in their early stage and focused 
on the design and preparation. The therapeutic and side effects have to be thoroughly 
tested since the conjugate, in a sense, is more like a new drug molecule which has the 
different structure as its “parents”. 
 
 
2.6.3 Micro- and Nano-particle Delivery System 
 
Poly(D,L-lactide-co-glycolide) (PLGA) is a FDA approved polymer which is 
widely used in formulation and drug delivery (149,150). Nucleic acids /PLGA particles 
could be made by conventional microsphere-making techniques, such as double emulsion 
(W/O/W) (119,151) and spray-drying techniques (120,152). However, by these methods, 
the encapsulation efficiency of nucleic acids in PLGA particles was as low as less than 1 
μg/mg (120,153) because the hydrophilicity of nucleic acids was not compatible with 
hydrophobic core of PLGA particles. Besides that, the hostile condition of preparation 
and the decrease in pH during the hydrolysis of PLGA also inactivated the loaded nucleic 
acids (154). Thus, encapsulation efficiency and the stability of nucleic acids are 
significantly influenced by preparation methods. Condensation of nucleic acids by 
cationic polymers before encapsulation in PLGA particles was reported to increase the 
encapsulation efficiency and protect the loaded nucleic acids from degradation. Capan et 
al. found complex formation with PLL (N/P 3:1 and 8:1) dramatically increased the 
encapsulation efficiency of supercoiled DNAs in PLGA/DNA micro particles (155). It 
was reported that other cationic materials, e.g. PEI, DOTMA, DC-Chol, or CTAB, could 
be used to make cationic PLGA/DNA nanospheres by a modified O/W emulsion solvent 
–evaporation method (152). Murata et al. prepared a long-term sustained release PLGA 
microspheres encapsulating anti-VEGF siRNA / cationic polymer complexes (arginine or 
branched PEI) using the W/O/W in-water drying method and observed the inhibition of 
tumor growth (119). The alternative strategy to improve the encapsulation efficiency was 
to synthesize new PLA grafted cationic polymers (156). The hydrophobicity and 
molecular weight of PLGA also have profound influence on the encapsulation efficiency 
of hydrophilic nucleic acids (153,154). Besides low encapsulation efficiency and 
inactivation of macromolecules, the slow drug release rate and burst release may hinder 
its application in the delivery of nucleic acids.  
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2.7 CONCLUSIONS 
 
The success of gene therapy is highly dependent on the delivery systems because 
of the unique nature of genetic materials compared to that of small molecules. Cationic 
lipids and polymers are widely used as transfection reagents for plasmid DNA, 
oligonucleotide and siRNA. Each of them has its advantages and disadvantages. The in 
vivo nucleic acid delivery is a complicated process and influenced by many factors. For 
example, cationic lipids are excellent transfection reagents and can efficiently transfect 
nucleic acids in vitro, while they exhibited low efficacies when administered 
intravenously (11) because of the induction of immune response and non specific 
distribution. However, cationic lipid-formulated plasmid DNA vaccine was reported to 
significantly enhance the antigen-specific antibody responses compared to naked plasmid 
DNA vaccine via intramuscular injection, possibly due to the induction of inflammatory 
cytokines like IFN-γ, IL-12, and IL-6 (157,158). PEGylation can significantly decrease 
non specific distribution and unexpected immune response. The cleavable linkage 
between PEG moiety and the cationic lipid or polymer is preferred since positively 
charged surface has to be exposed to trigger the endocytosis and endosomal escape. 
Modification of gene carriers with ligands may be another efficient way to impart the cell 
specific delivery. The interaction, either electrostatic or other forces, between nucleic 
acids and cationic carriers should be strong enough to make sure the lipo(poly)–plexes 
stable before cellular internalization. Thereafter, the complexes commonly locate in 
endosomes. The endosomal escape is an important step for a gene medicine to take action. 
The endosomal escape could be enhanced by “proton sponge effect” or lipid fusion. Then 
the loaded nucleic acids should be dissociated from the complexes and released in the 
cytoplasm or be translocated into nucleus. Any problems in each step may cause the 
whole delivery process fail. In this area, a great deal of work needs to be done so that we 
could have a comprehensive understanding of nucleic acid delivery process. The 
commonly used cationic carriers could also be used for siRNA delivery. However, 
siRNA is a short molecule compared to DNA and has different behaviors when mixing 
with cationic carriers. The optimized delivery condition for DNA may not be suitable for 
ODN or siRNA delivery (58). A variety of specific delivery systems have been developed 
to effectively target siRNAs to malignant cells. For example, lipid or polymer based 
siRNA conjugates have shown to be effective in vitro and in vivo (121). Since most 
siRNA conjugates are not positively charged, they are more suitable for in vivo delivery. 
 
The side effects of lipid or polymeric carriers have to be thoroughly studied 
although they were reported safer than viral vectors. The therapeutic applications of these 
carriers are still limited although some exciting progress has been achieved in various 
research areas, including the increased understanding of the biological processes involved 
in nucleic acid delivery, the technology to increase the chemical stability and therapeutic 
efficacy of nucleic acid, and the innovative design of new functional materials and 
delivery systems. To design a perfect lipid or polymeric nucleic acid delivery system, we 
still have a long way to go.  
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CHAPTER 3. STRUCTURAL AND FORMULATION FACTORS INFLUENCING 
PYRIDINIUM LIPID-BASED NCLEIC ACID DELIVERY* 
 
 
3.1 INTRODUCTION 
 
Cationic liposomes are the most commonly used synthetic carriers for delivery of 
oligonucleotides, siRNAs and plasmid DNA. The three basic components of a cationic 
lipid, which affect gene expression or silencing, include (i) a hydrophobic lipid anchor 
group, such as fatty acid chains of various lengths and unsaturation states, or cholesterol, 
which helps in forming liposomes and exchanging lipids in cell membrane (12), (ii) 
linker group, such as an ester, ether, amide, or carbamate, which binds the polar group to 
the lipid moiety and determines the stability and biodegradability of the cationic lipid 
(159), and (iii) a positively charged hydrophilic head group, such as mono- or poly-amine 
group, which interacts with pDNA via electrostatic interaction, leading to its 
condensation and enhanced the cellular uptake (37,114). Understanding of these 
structural parameters is essential for the rational design of efficient cationic lipid-based 
transfection reagents. Transfection efficiency of cationic liposomes greatly depends on (i) 
the extent of DNA condensation, (ii) increased cellular uptake due to ionic and/or 
hydrophobic interaction with negatively charged biological surfaces, and (iii) membrane 
fusion via transient membrane destabilization to achieve delivery into the cytoplasm 
while avoiding degradation in the lysosomal compartment (52,160). 
 
Significant progress has been made in the design and function of cationic lipids 
since the introduction in 1987 of the transfection reagent Lipofectin, which is a 1:1 w/w 
mixture of the cationic lipid N-[1-(2,3-dioleoyloxy)propel]-N,N,N-trimethylammonium 
(DOTMA) and DOPE (22). Many cationic lipids bearing either a single tertiary or 
quaternary ammonium head group or which contain protonatable polyamines linked to 
dialkyl or cholesterol anchors have been designed for transfection of a variety of cell 
types in culture (24,27,45). Commercially available cationic lipids used as liposomes or 
alone for gene delivery include DOTMA (Lipofectin); 2,3-dioleyloxy-N-[2-spermine 
carboxamide] ethyl-N,N-dimethyl-1-propanammonium trifluoroacetate (DOSPA, 
Lipofectamine), 1,2-bis(oleoyloxy)-3-(trimethylammonio) propane (DOTAP), N-[1-(2,3-
dimyristyloxy)propyl]-N,N-dimethyl-N-(2-hydroxyethyl) ammonium bromide (DMRIE), 
3β-[N-(N, N’-dimethylaminoethane) carbamoyl] cholesterol (DC-Chol), and dioctadecyl 
amidoglyceryl spermine (DOGS, Transfectam) and dimethyldioctadecylammonium 
bromide (DDAB) (22-26,158,160,161). A few such compounds have also been used in 
initial clinical studies. However, many of the cationic lipids used in early clinical trials 
such as DC-Chol, DMRIE, and GL-67, although effective in vitro, have proven 
inefficient in vivo, especially when compared with viral vectors (28,29).  
 
Various heterocyclic cationic lipids had been studied and used for gene delivery.  
_______________________________ 
* Adapted with permission from American Chemical Society. Zhu, L., Lu, Y., Miller, D. 
D., and Mahato, R. I. (2008) Structural and formulation factors influencing pyridinium 
lipid-based gene transfer. Bioconjug Chem 19, 2499-512.  
27 
 
Some of them showed higher transfection efficiency and lower cytotoxicity compared to 
cationic lipids with linear primary amines or polyamines as the head group (162). 
Pyridinium heterocyclic ring in the cationic amphiphile was first introduced in 1940s, 
which had antiseptic and antibiotic properties (26,163). Upon the invention of 
pyridinium-based cationic lipids, a series of these lipids have been developed and some 
of them have been reported to reach or surpass the transfection efficiency of commercial 
cationic lipid formulations, both in vitro and vivo, while maintaining low cytotoxicity 
(31,32,34,164,165). 
 
In this study, we synthesized a series of pyridinium lipids containing a 
heterocyclic positively charged ring linked to different types of fatty acids via ester or 
amide spacers. Following purification and characterization of these cationic lipids using 
1H NMR, 13C NMR and mass spectrometry, cationic liposomes were prepared using 
DOPE or cholesterol as a co-lipid, followed by determination of particle size and zeta 
potential. Reporter gene expression and cytotoxicity were determined after transfection of 
Chinese Hamster Ovary (CHO) cells, hepatocarcinoma (CRL1830) cells and prostate 
cancer (C4-2) cells with green fluorescent protein (GFP) or luciferase expression plasmid 
DNA after complex formation with cationic liposomes. Factors influencing gene transfer, 
including charge ratio (N/P) between cationic liposomes and pDNA, cationic lipid / co-
lipid ratio, linker type, fatty acid carbon chain length, degree of saturation, configuration 
of double bond, the presence of serum and cell type were studied. The pyridinium lipid 
was also tested in the delivery of siRNA and gene silencing study. 
 
 
3.2 EXPERIMENTAL PROCEDURES 
 
 
3.2.1 Materials 
 
1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) was purchased from 
Avanti Polar Lipids (Alabaster, AL). Alexa Fluor® Red fluorescent siRNA, firefly 
luciferase siRNA (sense strand: CUU ACG CUG AGU ACU UCG A[dt][dt], antisense 
strand:UCG AAG UAC UCA GCG UAA G[dt][dt]), Lipofectamine, Lipofectmine 2000, 
G418, DMEM and RPMI1640 were purchased from Invitrogen Corporation (Carlsbad, 
CA). Heat-inactivated fetal bovine serum (FBS) and penicillin (10000 units/mL penicillin 
G sodium)-streptomycin solution (10000 µg/mL streptomycin sulfate) in 0.85% saline 
were purchased from Mediatech, Inc. (Herndon, VA). Luciferase Assay Kit and Cell 
Culture Lysis Reagent 5 × (CCLR) were procured from Promega Corporation (Madison, 
WI). QIAfilter plasmid maxi kit was purchased from Qiagen, Inc. (Valencia, CA); BCA 
protein assay kit from Pierce (Rockland, IL); pCMS-EGFP plasmid was procured from 
BD Biosciences Clontech (Palo Alto, CA) and pcDNA3-Luc plasmid was a kind gift 
from Expression Genetics, Inc. (Huntsville, AL). All reagents used for lipid synthesis 
were purchased from Sigma-Aldrich Chemical Co. (St. Louis, MO) and Fisher Scientific 
(Pittsburgh, PA) and were used without further purification. 
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3.2.2 Synthesis of Pyridinium Lipids 
 
3.2.2.1 General Methods. 
 
Routine thin layer chromatography (TLC) was performed on aluminum backed 
Uniplates. (Analtech, Newark, DE). 1H NMR spectra were obtained on a Bruker AX 300 
(Billerica, MA) or Varian Inova-500 (Palo Alto, CA) spectrometer. Chemical shifts for 
1H NMR were reported as parts per million (ppm) relative to tetramethylsilane (TMS) in 
deuterated chloroform (CDCl3) as internal standard. 13C NMR spectra were obtained on a 
Bruker AX 300 spectrometer, operating at 75.5 MHz. To make sure the final results 
reliable we used two mass spectrometers, conventional mass and high-resolution mass 
(HRMS) to characterize the synthesized pyridinium lipids. Conventional mass spectral 
data was collected on a Bruker ESQUIRE electrospray/ion trap instrument in positive and 
negative ion modes. High-resolution mass measurements were obtained using a 
Micromass Q-TOF2 mass spectrometer. HRMS samples were dissolved in 50% 
acetonitrile, 0.1% Formic acid, and were infused by syringe (0.4 µL/min).To make the 
paper easier to be read we only list the HRMS data. 
 
Pyridinium amide cationic lipids 4-13 and pyridinium ester cationic lipids 14-18 
were synthesized as described by Illies et al. (32) and their visual structures with 
minimized energy were simulated with the Chem3D Pro software, version 10.0 
(CambridgeSoft Corp., Cambridge, MA) using MM2 molecular mechanics routine 
toward a 0.1 rms gradient, which are shown in Table 3.1. Figure 3.1 outlines a synthesis 
route via the corresponding pyrylium salts. Mesityl oxide was monoacylated with fatty 
acid chloride in the presence of aluminum chloride to yield pyrylium chloroaluminate, 
which was subsequently converted into more stable hexafluorophosphate 1, for using as a 
key intermediate to react with different primary amines, yielding aminoethylpyridinium 
hexafluorophosphate 2 and hydroxyethylpyridinium hexafluorophosphate 3. Acylation of 
these pyridinium salts with different types of fatty acid chlorides afforded the final 
pyridinium amide cationic lipids 4-13 and pyridinium ester cationic lipids 14-18, which 
were purified with chromatography on silica gel and recrystallized from ethanol. 
 
3.2.2.2 Synthesis of Pyridinium Amide Cationic Lipids 4-13 
 
Aminoethylpyridinium hexafluorophosphate 2, compounds 4 and 5 were 
synthesized as described by Ilies et al.(32) and the spectra were the same as those 
reported previously. 
 
4, 6-Dimethyl-2-tetradecyl-1-[2-(9Z)-hexadec-9-enoylamidoethyl] pyridinium 
hexafluorophosphate 6. Yield: 89.9 %; 1H NMR (CDCl3), δ, ppm: 7.41 (s, 1H, H-5 
pyridinium), 7.38 (s, 1H, H-3 pyridinium), 6.75 (t, 1H, J = 6.0 Hz), 5.33 (m, 2H, J = 5.4 
Hz), 4.56 (t, 2H, J = 6.9 Hz), 3.63 (dt, 2H, J = 6.9 Hz, 6.6 Hz, CONHCH2), 3.17 (t, 2H, J 
= 7.5 Hz, CαPy-CH2), 2.90 (s, 3H, CH3 α-Pyridinium), 2.55 (s, 3H, CH3 -Pyridinium), 
2.18 (t, 2H, J = 7.5 Hz, NHCOCH2), 1.99 (4 H, br), 1.72 (quint., 2H, CαPy-CH2CH2), 
1.47 (m, 2H, NHCOCH2CH2), 1.25 (s, 38H, CH2 from both of alkyl chains), 0.88 (t, 6H, 
CH3 of alkyl chains); 13C NMR (300 M, CDCl3), 175.23 (C=O), 159.07, 158.14,  
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Table 3.1 Energy minimized structures and melting points of pyridinium lipids. 
 
Carbon chain 
legnth and type 
Compound 
ID Amide M.P. 
Compound 
ID Ester M.P. 
C14:0 4 
 
73.6 ºC 14 
 
72.3 ºC 
C15:0    15 
 
81.7 ºC 
C16:0 5 
 
80.7 ºC 16 
 
77.1 ºC 
C18:0 8 83.8 ºC 17 
 
74.4 ºC 
C18:0, branch 13 
 
-16.3 ºC    
C16:1, cis-9 6 
 
36.8 ºC    
C16:1, trans-9 7 63.5 ºC    
C18:1, cis-9 9 
 
50 ºC 18 48.7 ºC 
C18:1, trans-9 10 
 
64.8 ºC    
C20:1, cis-11 11 
 
50.4 ºC    
C20:1, trans-11 12 
 
69.4 ºC    
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Figure 3.1 Synthesis scheme of pyridinium lipids. 
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155.05 (C-2, C-4 and C-6 pyridium), 130.41, 130.28 (CH=CH), 128.68, 127.32 (C-3 and 
C-5 pyridium), 50.55 (CαPy-CH2), 38.25 (CβPy-CH2),  35.97, 33.25, 32.59, 32.57, 31.92, 
31.75, 29.70, 29.69, 29.65, 29.64, 29.63, 29.63, 29.59, 29.39, 29.34, 29.29, 29.29, 29.24, 
29.21, 29.06, 29.03, 28.84, 25.40, 22.67, 22.63, 21.73, 21.51, 14.05, 14.05; HRMS calcd 
for C39H71N2O+, Mr = 583.5566, found 583.5568 . 
 
4, 6-Dimethyl-2-tetradecyl-1-[2-(9E)-hexadec-9-enoylamidoethyl] pyridinium 
hexafluorophosphate 7. Yield: 81.5 %; 1H NMR (300 M, CDCl3), δ, ppm: 7.42 (s, 1H, 
H-5 pyridinium), 7.37 (s, 1H, H-3 pyridinium), 6.75 (t, 1H, J = 6.0 Hz), 5.37 (m, 2H), 
4.55 (t, 2H, J = 6.6Hz), 3.62 (dt, 2H, J = 6.6 Hz, 6.3 Hz, CONHCH2), 3.17 (t, 2H, J = 7.5 
Hz, CαPy-CH2), 2.90 (s, 3H, CH3 α-Pyridinium), 2.54 (s, 3H, CH3 -Pyridinium), 2.17 (t, 
2H, J = 7.5 Hz, NHCOCH2), 1.95 (4H, br), 1.72 (quint., 2H, CαPy-CH2CH2), 1.46 (quint., 
2H, NHCOCH2CH2), 1.25 (s, 38H, CH2 from both of alkyl chains), 0.87 (t, 6H, CH3 of 
alkyl chains); 13C NMR (300 M, CDCl3), 174.67 (C=O), 158.47, 157.54, 154.51 (C-2, C-
4, C-6 pyridinium), 129.37, 129.25 (CH=CH), 128.11, 126.72 (C-3 and C-5 pyridium), 
49.97 (CαPy-CH2), 37.64 (CβPy-CH2),  36.38, 32.67, 31.35, 31.21, 29.17, 29.11, 29.09, 
29.08, 29.07, 29.02, 28.82, 28.77, 28.72, 28.70, 28.69, 28.65, 28.60, 28.55, 28.49, 28.40, 
26.66, 26.65, 24.83, 22.09, 22.06, 21.14, 20.92, 13.49, 13.48; HRMS calcd for 
C39H71N2O+, Mr = 583.5566, found 583.5562.  
 
4, 6-Dimethyl-2-tetradecyl-1-(2-octadecanoylamidoethyl) pyridinium 
hexafluorophosphate 8. Yield: 87.5 % ; 1H NMR (CDCl3), δ, ppm: 7.41 (s, 1H, H-5 
pyridinium), 7.38 (s, 1H, H-3 pyridinium), 6.77 (t, 1H, J = 6.0Hz), 5.37 (m, 2H, J = 
19.2Hz), 4.55 (t, 2H, J = 6.9Hz), 3.62 (dt, 2H, J = 6.9 and 6.0 Hz, CONHCH2), 3.17 (t, 
2H, J = 7.2 Hz, CαPy-CH2), 2.90 (s, 3H, CH3 α-Pyridinium), 2.54 (s, 3H, CH3 -
Pyridinium), 2.17 (t, 2H, NHCOCH2), 1.95 (4H, br, ), 1.72 (quint., 2H, CαPy-CH2CH2), 
1.48 (quint., 2H, NHCOCH2CH2), 1.25 (s, 50H, CH2 from both of alkyl chains), 0.88 (t, 
6H, CH3 of alkyl chains); 13C NMR (300 M, CDCl3), 175.15 (C=O), 159.00, 158.06, 
155.03 (C-2, C-4, C-6 pyridinium), 128.64, 127.24 (C-3 and C-5 pyridium),  50.49 
(CαPy-CH2), 38.17 (CβPy-CH2),  35.94, 33.19, 31.89, 31.88, 29.67, 29.66, 29.66, 29.65, 
29.64, 29.63, 29.63, 29.62, 29.61, 29.61, 29.60, 29.55, 29.49, 29.35, 29.33, 29.32, 29.31, 
29.30, 29.26, 29.25, 29.22, 29.02, 25.37, 22.63, 22.63, 21.67, 21.42, 14.01, 14.01;  
HRMS calcd for C41H77N2O+, Mr = 613.6036, found 613.6036. 
 
4, 6-Dimethyl-2-tetradecyl-1-(2-oleoylamidoethyl) pyridinium 
hexafluorophosphate 9.  Yield: 62.3%;   1H NMR (CDCl3), δ, ppm: 7.41 (s, 1H, H-5 
pyridinium), 7.38 (s, 1H, H-3 pyridinium), 6.77 (t, 1H, J = 6.0Hz, CONH), 5.33 (2H, t, 
HC=CH), 4.56 (t, 2H, J = 6.9Hz), 3.63 (dt, 2H, J = 6.9 and 6.0 Hz, CONHCH2), 3.17 (t, 
2H, J = 7.5 Hz, CαPy-CH2), 2.90 (s, 3H, CH3 α-Pyridinium), 2.55 (s, 3H, CH3 -
Pyridinium), 2.18 (t, 2H, NHCOCH2), 1.99 (q, 4H), 1.72 (quint., 2H, CαPy-CH2CH2), 
1.47 (quint., 2H, NHCOCH2CH2), 1.25 (s, 42H, CH2 from both of alkyl chains), 0.88 (t, 
6H, CH3 of alkyl chains); 13C NMR (300 M, CDCl3), 175.20 (C=O), 159.07, 158.13 , 
155.05 (C-2, C-4, C-6 pyridinium), 129.95, 129.81 (CH=CH), 128.68, 127.31 (C-3 and 
C-5 pyridium), 50.55 (CαPy-CH2), 38.24 (CβPy-CH2),  35.96, 33.24, 31.91, 31.90, 29.78, 
29.75, 29.68, 29.67, 29.66, 29.64, 29.63, 29.58, 29.51, 29.38, 29.33, 29.32, 29.29, 29.28, 
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29.28, 29.26, 29.25, 29.24, 29.18, 29.06, 27.23, 25.39, 22.66, 21.71, 21.49, 14.05, 14.05;  
HRMS calcd for C41H75N2O+, Mr = 611.5879, found 611.5872. 
 
4, 6-Dimethyl-2-tetradecyl-1-[2-(9E)-Octadec-9-enoylamidoethyl] pyridinium 
hexafluorophosphate 10. Yield: 56.5 %; 1H NMR (CDCl3), δ, ppm: 7.42 (s, 1H, H-5 
pyridinium), 7.37 (s, 1H, H-3 pyridinium), 6.76 (t, 1H, J = 6.3Hz), 5.37 (t, 2H, HC=CH , 
J = 19.2 Hz), 4.57 (t, 2H, J = 6.9Hz), 3.63 (dt, 2H, J = 6.9 and 6.3 Hz, CONHCH2), 3.17 
(t, 2H, J = 7.8 Hz, CαPy-CH2), 2.90 (s, 3H, CH3 α-Pyridinium), 2.56 (s, 3H, CH3 -
Pyridinium), 2.18 (t, 2H, NHCOCH2), 1.99 (br, 4H), 1.74 (quint., 2H, CαPy-CH2CH2), 
1.46 (quint., 2H, NHCOCH2CH2), 1.25 (s, 42H, CH2 from both of alkyl chains), 0.87 (t, 
6H, CH3 of alkyl chains); 13C NMR (300 M, CDCl3), 175.14 (C=O), 158.98, 158.06 , 
155.02 (C-2, C-4, C-6 pyridinium), 130.36, 130.21 (CH=CH), 128.63, 127.23 (C-3 and 
C-5 pyridium), 50.47 (CαPy-CH2), 38.16 (CβPy-CH2),  35.91, 33.17, 32.54, 32.51, 31.86, 
31.84, 29.62, 29.63, 29.62, 29.61, 29.60, 29.59, 29.58, 29.53, 29.42, 29.34, 29.28, 29.23, 
29.24, 29.20, 29.18, 29.15, 29.01, 28.98, 25.34, 22.60, 22.61, 21.65, 21.41, 13.99, 13.99; 
HRMS calcd for C41H75N2O+, Mr = 611.5879, found 611.5870. 
 
4, 6-Dimethyl-2-tetradecyl-1-[2-(11Z)-eicos-11-enoylamidoethyl] pyridinium 
hexafluorophosphate 11. Yield: 79.8 %; 1H NMR (CDCl3), δ, ppm: 7.41 (s, 1H, H-5 
pyridinium), 7.38 (s, 1H, H-3 pyridinium), 6.78 (t, 1H, J = 6.3 Hz), 5.34 (m, 2H, 
HC=CH ), 4.56 (t, 2H, J = 6.6Hz), 3.63 (dt, 2H, J = 6.6 and 6.3 Hz, CONHCH2), 3.17 (t, 
2H, J = 7.8 Hz, CαPy-CH2), 2.90 (s, 3H, CH3 α-Pyridinium), 2.55 (s, 3H, CH3 -
Pyridinium), 2.18 (t, 2H, NHCOCH2), 1.99 (br, 4H), 1.72 (quint., 2H, CαPy-CH2CH2), 
1.57-1.42 (m, 2H, NHCOCH2CH2), 1.25 (s, 46H, CH2 from both of alkyl chains), 0.88 (t, 
6H, CH3 of alkyl chains); 13C NMR (300 M, CDCl3), 175.23 (C=O), 159.06, 158.13, 
155.06 (C-2, C-4, C-6 pyridinium), 129.90, 129.90 (CH=CH), 128.69, 127.31 (C-3 and 
C-5 pyridium), 50.54 (CαPy-CH2), 38.23 (CβPy-CH2),  35.97, 33.24, 31.92, 31.90, 29.81, 
29.80, 29.78, 29.69, 29.67, 29.65, 29.64, 29.59, 29.54, 29.52, 29.50, 29.39, 29.35, 29.32, 
29.30, 29.29, 29.29, 29.28, 29.24, 29.06, 27.25, 27.23, 25.41, 24.78, 22.66, 21.72, 21.49, 
14.05, 14.05;  HRMS calcd for C43H79N2O+, Mr = 639.6192, found 639.6193. 
 
4, 6-Dimethyl-2-tetradecyl-1-[2-(11E)-eicos-11-enoylamidoethyl] pyridinium 
hexafluorophosphate 12. Yield: 58.8 %; 1H NMR (CDCl3), δ, ppm: 7.41 (s, 1H, H-5 
pyridinium), 7.38 (s, 1H, H-3 pyridinium), 6.78 (t, 1H, J = 6.0Hz), 5.38 (t, 2H, HC=CH), 
4.57 (t, 2H, J = 6.6Hz), 3.64 (dt, 2H, J = 6.9 and 6.0 Hz, CONHCH2), 3.17 (t, 2H, J = 7.8 
Hz, CαPy-CH2), 2.90 (s, 3H, CH3 α-Pyridinium), 2.56 (s, 3H, CH3 -Pyridinium), 2.18 (t, 
2H, NHCOCH2), 1.96 (br, 4H), 1.71 (quint., 2H, CαPy-CH2CH2), 1.48 (quint., 2H, 
NHCOCH2CH2), 1.25 (s, 42H, CH2 from both of alkyl chains), 0.87 (t, 6H, CH3 of alkyl 
chains); 13C NMR (300 M, CDCl3), 175.27 (C=O), 159.11, 158.16 , 155.04 (C-2, C-4, C-
6 pyridinium), 130.36, 130.36 (C=C), 128.68, 127.35 (C-3 and C-5 pyridium), 50.59 
(CαPy-CH2), 38.27 (CβPy-CH2),  35.98, 33.28, 32.60, 31.92, 31.91, 29.70, 29.69, 29.69, 
29.68, 29.68, 29.67, 29.67, 29.66, 29.65, 29.64, 29.59, 29.49, 29.49, 29.39, 29.35, 29.32, 
29.30, 29.29, 29.19, 29.07, 25.40, 25.40, 22.66, 22.66, 21.74, 21.54, 14.05, 14.05;   
HRMS calcd for C43H79N2O+, Mr = 639.6192, found 639.6196. 
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4, 6-Dimethyl-2-tetradecyl-1-[2-(2-heptyl-undecanoyl)-amidoethyl] 
pyridinium hexafluorophosphate 13. Yield: 77.3 %; 1H NMR (CDCl3), δ, ppm: 7.41 (s, 
1H, H-5 pyridinium), 7.37 (s, 1H, H-3 pyridinium), 6.78 (1H, t, 1H, J = 6.3 Hz), 4.55 (t, 
2H, J = 6.6Hz), 3.66 (dt, 2H, J = 6.6 and 6.6 Hz, CONHCH2), 3.22 (t, 2H, J = 6.9 Hz, 
CαPy-CH2), 2.93 (s, 3H, CH3 α-Pyridinium), 2.55 (s, 3H, CH3 -Pyridinium), 2.12 (quint., 
1H, NHCOCH), 1.71 (quint., 2H, CαPy-CH2CH2), 1.46 (quint., 4H, NHCOCH(CH2)2), 
1.25 and 1.23 (s, s, 46H, CH2 from both of alkyl chains), 0.88-0.84 (m, 9H, CH3 of alkyl 
chains); 13C NMR (300 M, CDCl3), 178.24 (C=O), 159.01, 158.01, 155.21 (C-2, C-4, C-6 
pyridinium), 128.71, 127.25 (C-3 and C-5 pyridium),  50.51 (CαPy-CH2), 47.17 
(C9H19CHC7H15), 38.03 (CβPy-CH2), 33.27, 32.68, 31.91, 31.89, 31.84, 29.72, 29.68,  
29.67, 29.66, 29.65, 29.65, 29.61, 29.61, 29.60, 29.53, 29.42, 29.34, 29.33, 29.30, 29.71, 
29.11, 29.06, 27.45, 27.38, 27.42, 26.77, 22.65, 22.62, 21.65, 21.44, 14.04, 14.04;  
HRMS calcd for C41H77N2O+, Mr = 613.6035, found 613.6037. 
 
3.2.2.3 Synthesis of Pyridinium Ester Cationic Lipids 14-18  
 
Hydroxyethylpyridinium hexafluorophosphate 3, compounds 14 and 16 were 
synthesized as the described method (32) and the spectra are the same as those reported 
in ref. 25. 
 
4, 6-Dimethyl-2-tetradecyl-1-(2-pentadecanoylhydroxyethyl) pyridinium 
hexafluorophosphate 15. Yield: 72.0%; 1H NMR (CDCl3), δ, ppm: 7.44 (s, 1H, H-5  
pyridinium), 7.39 (s, 1H, H-3 pyridinium), 4.80 (t, 2H, J = 5.7 Hz, COOCH2), 4.47 (t, 2H, 
J = 5.7z),  3.04 (t, 2H, J = 7.8 Hz, CαPy-CH2), 2.87 (s, 3H, CH3 -Pyridinium), 2.55 (s, 
3H, CH3 -Pyridinium), 2.25 (t, 2H, J = 7.5Hz, COCH2), 1.79 (cv, 2H, J = 7.5Hz,), 1.48 
(cv, 2H, COCH2CH2), 1.25, 1.26 (s, 44H, CH2 from both of alkyl chains), 0.88 (t, 6H, 
CH3 of alkyl chains); 13C NMR (300 M, CDCl3), 173.00 (C=O), 158.63, 158.56 , 155.43 
(C-2, C-4, C-6 pyridinium), 128.81, 126.90 (C-3 and C-5 pyridium), 60.68 (CαPy-CH2), 
49.94 (CβPy-CH2), 33.76, 33.38, 31.92, 29.68, 29.68, 29.67, 29.67, 29.66, 29.66, 29.65, 
29.65, 29.64, 29.60, 29.59, 29.59, 29.58, 29.45, 29.36, 29.35, 29.34, 29.22, 29.19, 29.06, 
28.37, 24.64, 22.67, 21.77, 21.63, 14.06, 14.06; HRMS calcd for C38H70NO2+, Mr = 
572.5406, found 572.5404. 
 
4, 6-Dimethyl-2-tetradecyl-1-(2-octadecanoylhydroxyethyl) pyridinium 
hexafluorophosphate 17.  Yield: 70.1%; 1H NMR (CDCl3), δ, ppm: 7.43 (s, 1H, H-5 
pyridinium), 7.40 (s, 1H, H-3 pyridinium), 4.81 (t, 2H, J = 6.0Hz, COOCH2), 4.49 (t, 2H, 
J = 6.0z), 3.06 (t, 2H, J = 7.5 Hz, CαPy-CH2), 2.89 (s, 3H, CH3 α-Pyridinium), 2.57 (s, 
3H, CH3 -Pyridinium), 2.26 (t, 2H, J = 7.5Hz, COCH2), 1.81 (quint., 2H, CαPy-
CH2CH2), 1.49 (quint., 2H, COCH2CH2), 1.26, 1.27 (s, 50H, CH2 from both of alkyl 
chains), 0.88 (t, 6H, CH3 of alkyl chains); 13C NMR (300 M, CDCl3), 173.00 (C=O), 
158.64, 158.55, 155.43 (C-2, C-4, C-6 pyridinium), 128.80, 126.90 (C-3 and C-5 
pyridium), 60.68 (CαPy-CH2), 49.95 (CβPy-CH2),  33.76, 33.38, 31.92, 31.92, 29.70, 
29.69, 29.69, 29.69, 29.68, 29.68, 29.67, 29.66, 29.65, 29.65, 29.64, 29.60, 29.58, 29.45, 
29.35, 29.35, 29.34, 29.22, 29.19, 29.06, 28.37, 24.65, 24.65, 22.67, 22.67, 21.77, 21.63, 
14.05, 14.05; HRMS calcd for C41H76NO2+, Mr = 614.5875, found 614.5880. 
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4, 6-dimethyl-2-tetradecyl-1-(2-oleoylhydroxyethyl) pyridinium 
hexafluorophosphate 18. Yield 69.5%; 1H NMR (CDCl3), δ, ppm: 7.43 (s, 1H, H-5 
pyridinium), 7.39 (s, 1H, H-3 pyridinium), 5.33 (m, 2H, CH from double bond in oleyl 
group), 4.80 (t, 2H, J = 6.0 Hz, COOCH2), 4.47 (t, 2H, J = 6.0 Hz), 3.05 (t, 2H, J = 7.5 
Hz, CαPy-CH2), 2.87 (s, 3H, CH3 α-Pyridinium), 2.55 (s, 3H, CH3 -Pyridinium), 2.25 (t, 
2H, J = 7.8 Hz, COCH2), 1.99 (q, 4H), 1.79 (quint., 2H, CαPy-CH2CH2), 1.48 (quint., 2H, 
COCH2CH2), 1.26 (s, 44H, CH2 from both of alkyl chains), 0.88 (t, 6H, CH3 of alkyl 
chains); 13C NMR (300 M, CDCl3), 172.99 (C=O), 158.75, 158.62, 155.52 (C-2, C-4, C-6 
pyridinium), 130.15， 129.59 (CH=CH), 128.76, 126.90 (C-3 and C-5 pyridium), 60.70 
(CαPy-CH2), 50.09 (CβPy-CH2),  33.75, 33.42, 31.92, 31.90, 29.76, 29.68, 29.68, 29.67, 
29.67, 29.65, 29.63, 29.57, 29.51, 29.44, 29.35, 29.34, 29.33, 29.29, 29.20, 29.19, 29.12, 
29.07, 29.02, 28.41, 27.25, 27.16, 24.64, 22.66, 21.79, 14.04, 14.04; HRMS calcd for 
C41H74NO2+, Mr = 612.5719, found 612.5725. 
 
 
3.2.3 Determination of Lipid Phase Transition Temperature and Melting Point 
 
Differential Scanning Calorimetry (DSC) studies were carried out to find the 
phase transition temperature and melting point with a DSC Q2000, TA Instruments (UK).  
About 5 mg of pyridinium lipid or lipid mixture was scanned from 0 to 100 °C at a scan 
rate of 2 °C/min. Data were analyzed using Universal Analysis software provided by TA 
instruments. 
 
 
3.2.4 Preparation of Pyridinium Liposomes and Lipoplexes 
 
A pyridinium lipid was dissolved in chloroform with a co-lipid, DOPE or Chol, at 
the molar ratio of 1:1, 2:1 and 4:1 to reach a final concentration of 1 mg/mL for the 
charged species. The solvent was removed by rotary evaporation and further dried under 
vacuum overnight to generate a thin lipid film. The lipid film was hydrated in sterile 
water at 60 °C, vortexed, and sonicated to yield cationic liposomes. Pyridinium 
liposomes were characterized for DNA condensation efficiency, particle size, and -
potential as described previously (114). Briefly, DNA condensation was determined by 
0.6% agarose gel electrophoresis at 10 V/cm for 100 min in 1 × TBE buffer, followed by 
ethidium bromide (EtBr) staining. The particle size and -potential of cationic liposomes 
and lipoplexes were determined at 25 °C by dynamic light scattering using Malvern 
Zetasizer® (Malvern Instruments, UK). 
 
 
3.2.5 In Vitro Transfection  
 
CHO cells were seeded in 24-well plates, and maintained in 0.5 mL of RPMI 
1640 medium containing 10% fetal bovine serum (FBS) under 5% CO2 at 37 °C for 24 h. 
The cell number was about 4 × 104 cells per well. GFP or luciferase expression plasmid 
(pCMS-EGFP or pDNA3-Luc) and cationic liposomes (different formulations) were 
diluted to 25μl by Opti-MEM® I Medium, respectively, and incubated for 5min at room 
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temperature. Lipoplexes were prepared by mixing plasmid and liposomes in equal 
volume, and incubated for 20min at room temperature to allow complex formation. 
Immediately before transfection, the media was removed, and cells were washed gently 
with sterile Phosphate Buffered Saline (PBS). Lipoplexes were added to each well, 
diluted to 0.5 mL by Opti-MEM® I Medium, and the plate was incubated under 5% CO2 
at 37 ºC for 6 h. Following transfection, the culture medium was replaced with RPMI 
1640 medium containing 10% FBS. GFP gene expression was observed under 
fluorescence microscopy (Olympus, Japan).  
 
For luciferase expression, the cells were collected and lysed. The cell lysate were 
measured for luciferase gene expression by Luciferase Assay Kit (Promega, Madison, 
WI). The total protein concentration was measured by bicinchoninic acid (BCA) Protein 
Assay Reagent (Pierce, Rockford, IL). Luciferase activity was normalized by the total 
protein content and expressed as relative light unit (RLU) per µg of protein (RLU/µg 
protein). 
 
To determine whether the presence of serum in the culture media affects the 
transfection efficiency of pyridinium lipids, we used RPMI 1640 culture medium 
containing 0, 5, 10, 15, 20, 30 and 40% FBS for transfection of CHO cells with 
pyridinium lipid-based lipoplexes and their transfection efficiencies were determined.  
To determine the effect of cell types on gene transfer, two more cell lines were used to 
determine transfection efficiency and cytotoxicity. Hepatocarcinoma cells (CRL 1830) 
were seeded with 0.5 mL of DMEM medium containing 10% FBS under 5% CO2 at 37 
°C. Prostate cancer cells (C4-2) cells seeded with RPMI 1640 medium containing 10% 
FBS under 5% CO2 at 37 °C. The cell number was about 4 × 104 cells per well for 24 
well plate for both of them. Luciferase expression and cytotoxicity were measured at the 
end of the transfection. 
 
To determine the cellular uptake of siRNA using pyridinium lipids, the Alexa 
Fluor® Red fluorescent siRNA was mixed with pyridinium liposome (7D1) at the charge 
ratio of 3:1 (+/-) to produce the siRNA/cationic liposome (CL) complexes according to 
the same procedure of the lipoplexes. After addition of the siRNA/CL complexes into the 
CHO cells, we took the picture using fluorescence microscopy at 2 h, 4 h, and 24 h. 
 
To make luciferase expression prostate cancer (C4-2) cells, cells were seeded in 
cell culture plate 24 h before being transfected with pRc/CMV2-Luc plasmid (from Dr. 
Shu Wang, National University of Singapore) for 18 h. Two days after transfection, cells 
were transferred into a T-25 cell culture flask and selected with 600 µg/mL G418. The 
resulting bioluminescent cells were maintained in media containing 300 µg/mL G418. To 
determine the gene silencing of siRNA using pyridinium lipids, luciferase siRNA was 
mixed with pyridinium liposome (7D1) at the charge ratio of 3:1 (+/-) to produce the 
siRNA/CL complexes according to the same procedure of the lipoplexes. The luciferase 
engineered C4-2 cells was seeded in the 24-well plate 24 h at the density of 4 × 104 cells 
per well before transfection of luciferase siRNA. The siRNA/CL complexes were 
transfected into C4-2 cells using the same protocol as the plasmid. The luciferase level 
was measured after 48 h. 
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3.2.6 Cytotoxicity Assay 
 
The cytotoxicity of lipoplexes at 48 h post-transfection was determined using 3-
[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay in CHO cells. 
Briefly 5 mg/mL stock solution of MTT in PBS was diluted 1:10 with complete growth 
medium. Four hours before the end of transfection study, cell culture medium was 
removed and replaced by MTT medium to achieve a final concentration of 0.5 mg/mL 
MTT. The plate was then incubated at 37 °C in 5% CO2 for 4 h. The medium was 
removed, blotted dry, and 200 µL of DMSO was added to each well to dissolve the 
formazan crystals. Finally the plate was read spectrophotometrically at 560 nm using a 
microplate reader (Bio-Rad, Hercules, CA). The relative cell viability was calculated as 
[Abs] sample/[Abs]control × 100%. 
 
 
3.2.7 Statistical Analysis 
 
Data were expressed as the mean ± standard deviation (SD). The difference 
between any two groups was determined by ANOVA. P < 0.05 was considered 
statistically significant. 
 
 
3.3 RESULTS 
 
 
3.3.1 Synthesis of Pyridinium Lipids  
 
The goal of this study was to synthesize a series of pyridinium lipids to determine 
the structure-activity relationship for enhanced gene delivery. All of these cationic lipids 
contain a heterocyclic pyridinium ring linked to a single alkyl chain fatty acid of different 
alkyl chain lengths (C14, C15, C16, C18 and C20), types (cis and trans isomers) and 
branched chain via ester and amide spacers. We synthesized not only the saturated and 
unsaturated even number carbon chain length but also carbon chain length of 15 (odd 
number) saturated analog and branched carbon chain saturated analog. Synthesis scheme 
of pyridinium lipids is shown in Figure 3.1. Briefly, mesityl oxide was monoacylated to 
yield pyrylium chloroaluminates, which were converted into pyrylium 
hexafluorophosphates (1) by hexafluorophosphoric acid. Pyrylium hexafluorophosphate 
was used as a key intermediate for reaction with different primary amines to form a 
pyridinium heterocyclic ring with different linkers in the final structure. Acylation of 
these pyridinium salts with different lengths and types of fatty acid chlorides afforded the 
final pyridinium lipids. Intermediate and final products of these pyridinium lipids were 
characterized by 1H NMR, 13C NMR and high-resolution mass spectrometry, and these 
results are included in the methods section.  
 
The structures with minimized energy of these lipids are listed in Table 3.1. Two 
side chains are much closer in energy minimized structures of unsaturated lipids than 
those of saturated lipids, which may facilitate the formation of lipid bilayers in 
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liposomes. The melting points of these lipids are listed in Table 3.1. More than half of 
these pyridinium lipids have melting points of more than 60 ºC. Increase in fatty acid 
chain length increased the melting point. Saturated lipids have higher melting points than 
unsaturated lipids except branched one. For unsaturated lipids, melting point of trans-
isomer is higher than that of cis-isomer of the same fatty acid chain length. Lipid phase 
transition temperatures of pure pyridinium lipids and lipid mixture are listed in Table 3.2. 
The lipids with amide linker showed lower phase transition temperature compared to 
lipids with ester linker. Increase in hydrophobic carbon chain length increased the phase 
transition temperature. At the same carbon chain length the phase transition temperature 
of trans isomer was higher than that of cis isomer. Phase transition temperature was 
higher when formulated with cholesterol than that when formulated with DOPE. Higher 
phase transition temperature makes liposome preparation difficult by rehydration of lipid 
films and extrusion. Therefore, probe sonication was used to produce small unilamellar 
vesicles (SUV) at 60 ºC. Sterile water was used as the suspension medium in cationic 
liposome preparation so as to prevent cationic liposome aggregation in long term storage 
in electrolytical buffer. 
 
 
3.3.2 Preparation and Characterization of Lipoplexes 
 
Transfection efficiency of lipoplexes is known to depend on the particle size and 
surface charge of liposomes and lipoplexes (166,167). Therefore, we determined the 
mean particle size, particle size distribution (PSD) and -potential of pyridinium 
liposomes prepared using different co-lipids and molar ratios of cationic lipid/co-lipid. 
The mean particle size of these liposomes was about 97.98 ± 4.31 nm, with the 
polydispersity index (PDI) of 0.32 ± 0.03, and -potential was 41.33 ± 4.10 mv (Table 
3.3). This suggests little difference in particle size and -potential among different 
liposome preparations. Pyridinium liposomes were stable and no aggregation was 
observed at 4 ºC during the experimental period. Lipoplexes were formed by simple 
mixing pyridinium liposomes and plasmid DNA. The degree of DNA condensation 
increased with the increase in charge ratio. However, migration of some free DNA was 
seen when lipoplexes were prepared at 0.5/1 to 2.5/1 (+/-). At the charge ratio of 3:1 (+/-) 
or above plasmid DNA was completely condensed in all the formulations, as evidenced 
by no band shift upon agarose gel electrophoresis of lipoplexes (data not shown). Upon 
lipoplex formation, the particle size, polydispersity index and -potential of lipoplexes 
were determined and found to be 124.33 ± 2.08 nm, 0.17 ± 0.02 and 28.07 ± 5.12 mv, 
respectively. Particle size distribution of lipoplexes (< 200 nm) was more than 90% at 0 h 
and more than 80% after 10 h. There was no significant change in the particle size, 
particle size distribution and -potential even at 10 h post-incubation at room temperature, 
suggesting these lipoplexes are fairly stable on storage. 
 
 
3.3.3 Factors Influencing Transfection 
 
The effect of various structure and formulation parameters on in vitro transfection 
efficiency of pyridinium lipids in CHO cells was examined as a function of linker (ester  
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Table 3.2 Determination of lipid phase transition temperature (ºC) by DSC. 
 
Type of hydrophobic 
anchor chain 
Linker Lipid, amide linker/Co-lipid (molar ratio 1:1) 
Ester Amide DOPE  CHOL  
C14:0 45.5-47.5 38.9-44.9 18.2-21.4 32.9-35.2 
C16:0 63.5-66.1 39.3-41.4 37.8-40.0 40.2-42.1 
C16:1, cis  29.7-31.1   
C16:1, trans  35.7-36.7   
C18:0 73.4-74.1 45.4-48.7 24.2-26.3 42.1-46.5 
C18:1, cis  31.4-32.1   
C18:1, trans  34.1-37.9   
C20:1, cis  36.7-39.6   
C20:1, trans  37.4-41.3   
 
Values are “onset to peak temperature”. 
N/A: no significant phase transition temperature was observed. 
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Table 3.3 Particle size and -potential of pyridinium cationic liposome and 
lipoplexes. 
 
Parameters Pyridinium cationic liposomes Lipoplexes (0h) Lipoplexes (10h) 
Particle size (nm) 97.98±4.31 124.33±2.08 128.33±1.53 
PDI 0.32±0.03 0.17±0.02 0.15±0.02 
PSD (<200 nm) >95% >90% >80% 
-potential (mv) 41.33±4.10 28.07±5.12 31.17±5.50 
 
PDI: polydispersion index; PSD: particle size distribution  
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vs. amide), hydrophobic carbon chain length (14, 16 and 18) and type (single vs. double), 
configuration of double bond (cis-isomer vs. trans-isomer), co-lipid type (DOPE vs. 
Chol), cationic lipid/co-lipid molar ratio (1:1, 2:1 and 4:1) and cationic lipid/DNA (+/-) 
charge (1:1, 3:1 and 5:1) ratio. Lipofectamine is one of the most commonly used 
transfection reagents and thus we selected this as the positive control for screening of our 
pyridinium lipids. Our purpose was to optimize our own cationic liposome formulations, 
not the transfection conditions of Lipofectamine. Therefore, we formulated 
Lipofectamine/plasmid complexes at 3/1 (+/-) charge ratio, which is in the range of the 
recommended conditions by the manufacturer. Transfection efficiency was reported as 
relative light units (RLU) per µg of total protein content.  
 
3.3.3.1 Charge Ratios 
 
Pyridinium lipid (C16:0, amide linker) was mixed with Chol at the cationic 
lipid/co-lipid ratio of 1:1 to prepare cationic liposomes, and lipoplexes were prepared by 
mixing with luciferase plasmid at the charge ratio of 1:1, 3:1 and 5:1 (+/-). Luciferase 
gene expression (Figure 3.2A) and cytotoxicity (Figure 3.2B) in CHO cells were 
determined at 48 h post-transfection. Luciferase gene expression levels increased with 
increasing lipid/DNA charge ratios from 1:1 to 5:1, while cell viability decreased slightly 
with increase in charge ratio to 5:1 (+/-). Compared to Lipofectamine, much higher 
transfection efficiency was observed at the charge ratios of 3:1 and 5:1 (+/-) groups but 
there was no significant difference between 3:1 and 5:1. Further, there was no significant 
difference in cytotoxicity between pyridinium liposomes and Lipofectamine. 
 
3.3.3.2 Type of Linkers 
 
Pyridinium lipids (C16:0 with ester and amide linkers) were used to prepare 
liposomes with DOPE and Chol at the cationic lipid/co-lipid molar ratio of 1:1. 
Following transfection of CHO cells with lipoplexes (3:1, +/-), GFP positive CHO cells 
were visualized under fluorescence microscopy at 48 h post-transfection. The cationic 
lipids with amide linkers significantly increased transfection efficiency in all liposomal 
formulations in CHO cells compared to their counterparts with ester linker, as evidenced 
by much higher levels of green fluorescence. This trend was confirmed by luciferase gene 
expression. (Figure 3.3). 
 
3.3.3.3 Cationic Lipid:Co-lipid Molar Ratios 
 
Pyridinium lipid with C16:0 fatty acid chain and amide linker was used to 
formulate liposomes with cholesterol at cationic lipid/co-lipid molar ratio of 1:1, 2:1 and 
4:1, and lipoplexes were prepared at the charge ratio of 3:l (+/-). At 48 h post-transfection, 
luciferase gene expression (Figure 3.4A) and cytotoxicity (Figure 3.4B) were measured. 
Pyridinium liposomes prepared at 1:1 and 2:1 cationic lipid/co-lipid molar ratios showed 
higher transfection efficiency compared to 4:1 molar ratio and Lipofectamine. Cell 
viability slightly decreased when the molar ratio of pyridinium lipid to Chol increased but 
no difference compared to Lipofectamine. So we decided to select 1:1 cationic lipid/co-
lipid molar ratio to prepare liposomes for further studies. 
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Figure 3.2 Effect of charge ratios on the transfection (A) and cytotoxicity (B) of 
CHO cells at 48 h after transfection of lipoplexes.  
Pyridinium  lipid 5 (C16:0, amide linker, trans-isomer) was mixed with cholesterol 
(Chol) at the cationic lipid/co-lipid ratio of 1:1 to prepare cationic liposomes, and 
lipoplexes were prepared by mixing with luciferase plasmid at the charge ratio of 1:1, 3:1 
and 5:1 (+/-). Luciferase gene expression and cytotoxicity in CHO cells were determined 
after 48 h post-transfection. The dose of pcDNA3-Luc plasmid was 0.2 µg/well for 4 × 
104 cells. 
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Figure 3.3 Effect of linker type on GFP gene (A) and luciferase gene (B) 
transfection efficiency and cytotoxicity (C) at 48 h after transfection of lipoplexes.  
For 2.3A, C16:0 lipid with amide linker and C16:0 lipid with ester linker were used to 
prepare cationic liposomes with co-lipid DOPE and cholesterol at the molar ratio of 1:1. 
Lipoplexes were formed by mixing with GFP plasmid at the charge ratio of 3:1 (+/-). 
GFP gene expression was observed at 48 h after transfection under fluorescence 
microscopy and normal light as control. The dose of pCMS-EGFP plasmid was 0.4 
µg/well for 4 × 104 cells.  
For 2.3B and 2.3C, Lipids with easter linker and lipids with amide linker were used to 
prepare cationic liposomes with DOPE at the molar ratio of 1:1. Lipoplexes were formed 
by mixing with luciferase plasmid at the charge ratio of 3:1 (+/-). Luciferase gene 
expression (B) and cytotoxicity (C) in CHO cells were determined at 48 h after 
transfection. The dose of pcDNA3-Luc plasmid was 0.2 µg/well for 4 × 104 cells. 
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Figure 3.4 Effect of cationic lipid/co-lipid molar ratios on transfection efficiency 
(A) and cytotoxicity (B).  
Lipid 5 (C16:0, amide linker) was used to prepare cationic liposomes with co-lipid 
cholesterol (Chol) at the molar ratio of 1:1, 2:1 and 4:1. Lipoplexes were formed by 
mixing with luciferase plasmid at the charge ratio of 3:1 (+/-). Luciferase gene expression 
and cytotoxicity in CHO cells were determined at 48 h after transfection. The dose of 
pcDNA3-Luc plasmid was 0.2 µg/well for 4 × 104 cells. 
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3.3.3.4 Type of Co-lipids 
 
Pyridinium lipids with amide linker but different fatty acid chain (C16:0 and 
C18:0) were used to prepare liposomes by mixing with DOPE and Chol at the molar ratio 
of 1:1, and lipoplexes were prepared at the charge ratio of 3:l (+/-). After 48 h post-
transfection, luciferase gene expression (Figure 3.5A) and cytotoxicity (Figure 3.5B) 
were measured. Chol as a co-lipid showed higher transfection efficiency in C16:0 amide 
lipid, on the contrary DOPE as a co-lipid showed higher transfection efficiency in C18:0 
amide lipid. Both of the formulations showed higher gene transfer than 
Lipofectamine/pDNA complexes formulated at 3:1 (+/-) charge ratio. No difference in 
cytotoxicity between pyridinium liposomes and Lipofectamine. 
 
3.3.3.5 Alkyl Chain Length 
 
Pyridinium lipids with amide linker and different alkyl chain length (C14:0, 
C16:0 and C18:0) were used to formulate liposomes with cholesterol at cationic lipid/co-
lipid molar ratio of 1:1. At 48 h post-transfection of CHO cells with lipoplexes, luciferase 
level was determined at 3:1 (+/-) charge ratio (Figure 3.6A). Cytotoxicity data was shown 
in Figure 3.6B. Pyridinium lipid with C14:0 and C16:0 showed much higher transfection 
efficiency compared to C18:0 and also higher than Lipofectamine at 3:1 (+/-) ratio. There 
was no difference in cytotoxicity compared to Lipofectamine for all the formulations 
except C14:0 lipid with amide linker, which showed the lowest level of cell viability. We 
also found that odd number (C15:0) and C18:0 branched carbon chain analogs could not 
increase the transfection efficiency (data not shown). 
 
3.3.3.6 Saturation of Alkyl Chain 
 
Pyridinium lipids (C16:0 and C16:1) were used to prepare cationic liposomes 
using Chol as a co-lipid at 1:1 molar ratio. At 48 h post-transfection of CHO cells with 
lipoplexes (3:1, +/-), luciferase gene expression (Figure 3.7A) and cytotoxicity (Figure 
3.7B) were measured. The trans-isomer showed slightly higher transfection efficiency 
than saturated lipid, and much higher transfection efficiency than its counterpart cis-
isomer. No significant difference in cell viability between pyridinium lipids and 
Lipofectamine. 
 
3.3.3.7 Configuration of Alkyl Chain 
 
Pyridinium lipids with different alkyl chain length (C16:1, C18:1 and C20:1) and 
different configuration (cis and trans) of double bond were used to formulate cationic 
liposomes with DOPE at the molar ratio of 1:1. At 48 h post-transfection of CHO cells 
with lipoplexes (3:1, +/-), luciferase gene expression (Figure 3.8A) and cytotoxicity 
(Figure 3.8B) were measured. The liposomes formulated with trans configuration lipids 
showed higher transfection efficiency compared to their counterpart lipids with cis 
configuration at the same fatty acid chain length. C16:1 trans isomer has much higher 
transfection efficiency than C18:1 and C20:1 trans isomers at the same type of  
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Figure 3.5 Effect of co-lipid type on transfection efficiency (A) and cytotoxicity 
(B).  
Lipids 5 (C16:0, amide linker) and 8 (C18:0, amide linker) were used to prepare cationic 
liposomes with co-lipid DOPE and cholesterol (Chol) at the molar ratio of 1:1. 
Lipoplexes were formed by mixing with luciferase plasmid at the charge ratio of 3:1  
(+/-). Luciferase gene expression and cytotoxicity in CHO cells were determined at 48 h 
after transfection. The dose of pcDNA3-Luc plasmid was 0.2 µg/well for 4 × 104 cells. 
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Figure 3.6 Effect of fatty acid chain length on transfection efficiency (A) and 
cytotoxicity (B).  
Lipids 4 (C14:0, amide linker), 5 (C16:0, amide linker) and 8 (C18:0, amide linker) were 
used to prepare cationic liposomes with co-lipid cholesterol (Chol) at the molar ratio of 
1:1. Lipoplexes were formed by mixing with luciferase plasmid at 3:1 (+/-) charge ratio.  
Luciferase gene expression and cytotoxicity in CHO cells were determined at 48 h after 
transfection. The dose of pcDNA3-Luc plasmid was 0.2 µg/well for 4 × 104 cells. 
  
C16:0 C18:0C14:0
0
20
40
60
80
100
120
4C
H
1
5C
H
1
8C
H
1
L
ip
of
ec
ta
m
in
e
C
on
tr
ol
C
el
l v
ia
bi
lit
y 
(%
)
(B)
P<0.05
0
100000
200000
300000
400000
500000
600000
4C
H
1
5C
H
1
8C
H
1
L
ip
of
ec
ta
m
in
e
C
on
tr
ol
L
uc
ife
ra
se
 (R
L
U
/μg
 p
ro
te
in
)
C16:0 C18:0C14:0
(A)
P<0.01
P<0.01
47 
 
 
 
 
Figure 3.7 Effect of degree of saturation on transfection efficiency (A) and 
cytotoxicity (B).  
Lipids 5 (C16:0, amide linker), 6 (C16:1, amide linker, cis-isomer) and 7 (C16:1, amide 
linker, trans-isomer) were used to prepare cationic liposomes with co-lipid cholesterol 
(Chol) at the molar ratio of 1:1. Lipoplexes were formed by mixing with luciferase 
plasmid at the charge ratio of 3:1 (+/-). Luciferase gene expression and cytotoxicity in 
CHO cells were determined at 48 h after transfection. The dose of pcDNA3-Luc plasmid 
was 0.2 µg/well for 4 × 104 cells. 
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Figure 3.8 Effect of alkyl chain configuration on transfection efficiency (A) and 
cytotoxicity (B).  
Lipids 6 (C16:1, amide linker, cis-isomer), 7 (C16:1, amide linker, trans-isomer), 9 
(C18:1, amide linker, cis-isomer), 10 (C18:1, amide linker, trans-isomer), 11 (C20:1, 
amide linker, cis-isomer) and 12 (C20:1, amide linker, trans-isomer) were used to prepare 
cationic liposomes with co-lipid DOPE at the molar ratio of 1:1. Lipoplexes were formed 
by mixing with luciferase plasmid at the charge ratio of 3:1 (+/-).  Luciferase gene 
expression and cytotoxicity in CHO cells were determined at 48 h after transfection. The 
dose of pcDNA3-Luc plasmid was 0.2 µg/well for 4 × 104 cells. 
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formulations. No significant difference in cell viability between all formulations and 
Lipofectamine. 
 
3.3.3.8 Influence of Serum on Gene Transfer 
 
Since serum is known to interfere with the transfection of lipoplexes, we 
transfected CHO cells with the lipoplexes prepared using two most potent pyridinium 
lipid-based liposome formulations (C16:0, amide: cholesterol at 1:1 molar ratio (5CH1) 
and C16:1, amide, trans: DOPE at 1:1 molar ratio (7D1)) in the presence of serum (0, 5, 
10, 15, 20, 30 and 40%). As shown in Figure 3.9, the formulation 7D1 showed 
significantly higher transfection efficiency compared to the formulation 5CH1 and 
Lipofectamine (formulated at 3:1, +/- charge ratio) at each serum concentration. The 
transfection efficiencies were decreased with increase in serum concentration. At the 
serum concentration of 30% and higher, 5CH1 and Lipofectamine lost their transfection 
ability when formulated at 3/1 (+/-) charge ratio, while 7D1 still kept high transfection 
efficiency. The luciferase gene expression in 7D1 treated cells at the serum concentration 
of 40% showed incredibly similar level compared to those of 5CH1 and Lipofectamine in 
the serum free medium. 
 
3.3.3.9 Different Cell Lines 
 
Two pyridinium lipid formulations (5CH1 and 7D1) based on cationic/co-lipid 
molar ratio of 1:1 and complex formation at 3:1 (+/-) charge ratio were tested in two 
additional cell lines, CRL 1830 and C4-2. At 48 h post-transfection, luciferase gene 
expression and cytotoxicity in CRL 1830 (Figure 3.10) and C4-2 (Figure 3.11) were 
measured. Both formulations worked very well in these two cell lines as evidence by 
more than 5-10 times of luciferase level compared to Lipofectamine when formulated at 
3/1 (+/-) charge ratio. There was no significant difference in cell viability between all 
formulations and Lipofectamine. These results suggest that the order of magnitude to 
which pyridinium lipid based formulations exceeds Lipofectamine 3/1 (+/-) formulation 
is cell type dependent. Nevertheless, in all cases, much higher transfection efficiency was 
obtained when transfection was carried out using pyridinium lipid with C16 fatty acid 
chain and amide linker. 
 
3.3.3.10 Transfection of siRNAs 
 
Since siRNA was widely used to silence the target gene in the cell culture, the 
transfection ability of pyridinium lipids was tested in the delivery of luciferase siRNA 
into the luciferase expression C4-2 cells. The pyridinium lipid formulation (7D1) was 
prepared using DOPE as the co-lipid at the molar ratio of 1:1. The luciferase 
siRNA/cationic liposome complexes were prepared at 3:1 (+/-) charge ratio and 
transfected into luciferase expression C4-2 cells. Lipofectamine 2000 was used at the 
same charge ratio as the pyridinium cationic liposomes and as the positive control. At 48 
h post-transfection, luciferase gene expression (Figure 3.12) was measured. Based on the 
data, both pyridinium lipids and Lipofectamine 2000 could transfect luciferase siRNAs 
into luciferase gene expression C4-2 cells and down-regulate the luciferase gene  
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Figure 3.9 Influence of serum on gene transfer.  
Lipids 5 (C16:0, amide linker) and 7 (C16:1, amide linker, trans-isomer) were used to 
prepare cationic liposomes with co-lipid DOPE and cholesterol at the molar ratio of 1:1. 
Lipoplexes were formed by mixing with luciferase plasmid at the charge ratio of 3:1  
(+/-). Luciferase gene expression and cytotoxicity in CHO cells were determined at 48 h 
after transfection. The dose of pcDNA3-Luc plasmid was 0.2 µg/well for 4 × 104 cells. 
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Figure 3.10 Transfection efficiency (A) and cytotoxicity (B) in hepatocarcinoma 
cells.  
Lipids 5 (C16:0, amide linker) and 7 (C16:1, amide linker, trans-isomer) were used to 
prepare cationic liposomes with co-lipid DOPE and cholesterol at the molar ratio of 1:1. 
Lipoplexes were formed by mixing with luciferase plasmid at the charge ratio of 3:1  
(+/-). Luciferase gene expression and cytotoxicity in CRL 1830 cells were determined at 
48 h after transfection. The dose of pcDNA3-Luc plasmid was 0.2 µg/well for 4 × 104 
cells. 
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Figure 3.11 Transfection efficiency (A) and cytotoxicity (B) in prostate cancer 
cells.  
Lipids 5 (C16:0, amide linker) and 7 (C16:1, amide linker, trans-isomer) were used to 
prepare cationic liposomes with co-lipid DOPE and cholesterol at the molar ratio of 1:1. 
Lipoplexes were formed by mixing with luciferase plasmid at the charge ratio of 3:1  
(+/-). Luciferase gene expression and cytotoxicity in C4-2 cells were determined at 48 h 
after transfection. The dose of pcDNA3-Luc plasmid was 0.2 µg/well for 4 × 104 cells. 
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Figure 3.12 Gene silencing of luciferase siRNA in luciferase engineered prostate 
cancer cells (C4-2) using pyridinium cationic liposomes.  
Lipids 7 (C16:1, amide linker, trans-isomer) were used to prepare cationic liposomes with 
co-lipid DOPE at the molar ratio of 1:1. Lipoplexes were formed by mixing with siRNAs 
at the charge ratio of 3:1 (+/-). Luciferase gene expression in C4-2 cells was determined 
at 48 h after transfection. The doses of Luc siRNA were 5, 10, 20, and 40 nM. 
Lipofectamine 2000 was used as the positive control. 
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expression even at the low dose of siRNAs. Transfection using pyridinium cationic 
liposomes showed relatively high gene down-regulation rate compared to Lipofectamine 
2000. 
 
3.3.3.11 Cellular Uptake Study of siRNAs Using Pyridinium Lipids 
 
The pyridinium lipid formulation (7D1) was prepared using DOPE as the co-lipid 
at the molar ratio of 1:1. The Alexa Fluor® Red Fluorescent siRNA/cationic liposome 
complexes were prepared at 3:1 (+/-) charge ratio and added into CHO cells. The photo 
was taken by fluorescence microscopy at 2, 4 and 24 h after addition of siRNA/CL 
complexes (Figure 3.13). Compared to free siRNAs at 24 h, complexation with 
pyridinium cationic liposomes significantly increased the cellular uptake of fluorescent 
siRNA even at 2 h after addition of siRNA/pyridinium cationic lipid. 
 
 
3.4 DISCUSSION 
 
The structural and formulation factors, such as lipid/DNA ratio, co-lipid type, and 
cationic lipid/co-lipid ratio have been shown to influence gene transfer efficiency both in 
vitro and in vivo (45,166,168). Pyridinium lipids have been shown to display higher 
transfection efficiency in cells that are not easily transfected by other cationic lipids, such 
as lipofectin, and transfect relatively a large number of cells (31). Therefore, here we 
report the effect of these parameters on the transfection efficiency of a series of 
pyridinium lipids. 
 
In general, transfection efficiency increases with increase in the charge ratio of 
lipoplexes until it becomes too toxic to the cells. To determine the structure-activity 
relationship of pyridinium lipid, we first determined the effect of cationic lipid/plasmid 
charge ratio on the transfection efficiency to find the best charge ratio for further 
evaluations. Based on our transfection data, lipoplexes prepared at the charge ratio of 3:1 
(+/-) showed much higher transfection efficiency compared to 1:1 (+/-), but no significant 
difference compared to 5:1 (+/-). There is no significant difference between pyridinium 
lipids and Lipofectamine in cytotoxicity. Therefore, the charge ratio was fixed to 3:1 in 
all the following experiments. 
 
Melting point, phase transition temperature, biodegradability and transfection 
efficiency are known to depend on the structure of the linker that binds to the polar head 
group to the hydrophobic lipid chains (52). Therefore, we determined the effect of amide 
and ester linkers on transfection efficiency and cytotoxicity. We used these linkers 
because they are biodegradable and thus could reduce the cytotoxicity of pyridinium 
lipids (32). As shown in Figure 3.3, the lipid with amide linker showed higher 
transfection efficiency compared to their counterparts with the ester linker regardless of 
the fatty acid chain length. The high transfection efficiency of amide linker lipids may be 
caused by their lower phase transition temperature (Table 3.2) which makes liposomal 
bilayer structure more stable in aqueous solution during transfection process and storage. 
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Figure 3.13 Cellular uptake of Alexa Fluor® Red Fluorescent siRNA in CHO cells 
using pyridinium cationic liposomes.  
Lipids 7 (C16:1, amide linker, trans-isomer) were used to prepare cationic liposomes with 
co-lipid DOPE at the molar ratio of 1:1. Lipoplexes were formed by mixing with siRNAs 
at the charge ratio of 3:1 (+/-). The photo was taken by fluorescence microscopy at 2, 4 
and 24 h after addition of siRNA/CL complexes. 
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The molar ratio of a cationic lipid to co-lipid is known to affect the phase 
transition temperature of cationic liposomes and the structure of lipoplexes. Therefore, 
we prepared cationic liposomes using pyridinium lipid and cholesterol at the molar ratio 
of 1:1, 2:1 and 4:1, as cholesterol has been reported to be superior to DOPE for 
pyridinium lipids (34). Luciferase gene expression (Figure 3.4A) and cytotoxicity (Figure 
3.4B) were influenced by the molar ratio of pyridinium lipid to Chol, with the highest 
transfection efficiency for the liposomes prepared at 1:1 cationic lipid/co-lipid molar ratio. 
Increase in the amount of Chol slightly decreased cytotoxicity of pyridinium liposomes.  
So we fixed cationic lipid/co-lipid molar ratio to 1:1 in other experiments. These results 
are in good agreements with the work of Illies et al. (34). 
 
DOPE and Chol are the most commonly used co-lipids in liposome preparation. 
The incorporation of fusogenic lipids such as DOPE improves the endosomal release by 
membrane fusion between the liposomal and endosomal bilayers (109,110). It had been 
also proved that DOPE could be a major driving force in promoting transfection of 
SAINT-2 based lipoplexes via the transformation of the lamellar DOPE-containing 
complex as prepared in water to the hexagonal phase when dispersed in a physiological 
salt solution (111). The use of Chol as a co-lipid has been reported to show enhanced in 
vivo gene expression, as Chol-containing liposomes efficiently interact with the cell 
membrane in the presence of serum (112). Based on our data, the use of both DOPE and 
Chol as co-lipids showed higher transfection efficiency of pyridinium lipids compared to 
Lipofectamine when lipoplexes were prepared at 3/1 (+/-) charge ratio. The selection of 
co-lipid was dependent on the type of cationic lipids. 
 
The hydrophobic chain length influences the shape of amphiphiles and 
supramolecular associations generated through the self-assembling process (32). 
Therefore, we synthesized a series of pyridinium lipids with different length of fatty acids 
to determine the influence of alkyl chain length on gene transfer. Pyridinium lipids with 
C14:0 and C16:0 fatty acid and amide linker formulated with Chol showed higher 
transfection efficiency compared to C18:0 lipid with the same linker (Figure 3.6A). Since 
C14:0 was more toxic than C16:0 but had similar transfection efficiency, we only 
synthesized C16:1, C18:1 and C20:1 for further evaluation. As shown in Figure 3.8A, 
C16:1 showed higher transfection efficiency compared to C18:1 and C20:1. Ilies et al. 
(2006) reported similar results (32). Van der Woude et al. (31) also reported significant 
reduction in transfection efficiency and cytotoxicity with elongation of the alkyl chain 
length to C18:0 (SAINT-5) relative to that of C16:0 (SAINT-1). Srilakshmi et al. (169) 
demonstrated that the transfection efficiency of cationic lipids was anchor-dependent 
when they studied the cationic lipids containing hydrophobic anchor chain ranging from 
C12 to C18. In their study, the lipid containing 16-carbon chain showed better 
transfection efficiency among these compounds, while lipids containing less than 14-
carbon anchor chain did not show any transfection, indicating that a minimum of 14-
carbon anchor length is essential for imparting transfection properties to their cationic 
lipids (170). Cationic lipids containing less than 14-carbon anchor chain do not form 
stable lipoplexes that are required for efficient cellular uptake of plasmid DNA. Non-
condensed plasmid DNA present in the lipoplexes either gets degraded by the serum 
proteins and/or enters into a non-productive pathway (170). On the contrary, the carbon 
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anchor chain will promote strong interaction between DNA and cationic lipid by 
hydrophobic strength besides electrostatic interaction, which will decrease the release of 
DNA from cationic liposomes, leading to further decrease in gene expression (164). A 
balance between the stability of the liposome in the medium and endosomal DNA release 
into the cytoplasm is important for efficient transfection efficiency (171). 
 
The degree of un-saturation and configuration of hydrophobic anchor chain can 
affect the transfection efficiency and cytotoxicity (31). The degree of un-saturation in 
lipid structure affects the fusogenicity of the lipid (Lα/HII transition) (42,43). Increase in 
the chain length of saturated hydrophobic anchors increases the phase transition 
temperature: 45.5, 63.5 and 73.4 for C14:0, C16:0 and C18:0 of pyridinium lipids with 
ester linkages; and 38.9, 39.3 and 45.4 for C14:0, C16:0 and C18:0 of pyridinium lipids 
with amide linkers (Table 3.2). The increase in phase transition temperature decreases 
fusogenicity, leading to decrease in transfection efficiency (44). Double bond in the fatty 
acid carbon chain will also decrease the melting point (Table 3.1). To investigate the 
relevance of cis versus trans orientation, we synthesized new lipids with one double bond 
(cis or trans) in the hydrophobic carbon chain. As apparent in Figures 3.7A and 3.8A 
trans-orientation (C16:1, C18:1 and C20:1) enhances the transfection efficiency 
compared to cis-oriented alkyl chains of the same length. This trend is in good agreement 
with the previous report by Van der Woude et al. (31). Based on our results shown in 
Figures 3.5A, 3.7A and 3.8A, we conclude that the trans-isomer worked better than cis 
and saturated lipids. 
 
The stability of the lipoplexes in the presence of serum is important for their in 
vivo efficacies (172,173). Increase in serum concentration significantly decreased the 
transfection efficiency (Figure 3.9). Serum contains nucleases and other enzymes, which 
would degrade plasmid DNA, and also contains proteins, such as albumin, which would 
inhibit the cellular association of the lipoplex (174). However, our lipid trans-isomer 
C16:1 showed excellent performance even at the serum concentration of 30% and above 
which Lipofectamine totally lost its transfection ability when lipoplexes were formulated 
at 3/1 (+/-) charge ratio. This finding suggests that C16:1 trans-isomer-based liposomes 
can be used for in vivo gene delivery. Gopal et al. (164) also demonstrated good 
transfection efficiency of glutamide-containing pyridinium lipids in the presence serum. 
 
Since pyridinium lipids could interact with the negatively charged molecules and 
form the condensed particles which facilitate the cellular uptake, it was expected to be 
used to deliver and enhance the cellular uptake of siRNAs. To study the silencing effect 
of luciferase siRNAs, we used luciferase expression cells. The data in Figure 3.12 
showed that pyridinium lipids enhanced the gene down-regulation rate higher than 
commercial product Lipofectamine 2000, which is specifically designed for siRNA 
delivery. The photos in Figure 3.12 showed that complexation with siRNAs increased the 
speed and extent of the cellular uptake compared to free siRNAs. 
 
A major issue of interest is obviously the understanding why pyridinium cationic 
lipid could improve transfection. Since a couple of papers have shown that the lipid with 
one or more pyridinium ring could significantly improve the transfection efficiency and 
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decrease the cytotoxicity. Obviously the pyridinium positively charged head group plays 
an important role in the improvement of transfection efficiency. It had been proved that 
the antimicrobial activity of alkyl pyridinium salts was associated with the cell leakage 
(175). This antimicrobial activity increased with increase in number of pyridinium head 
groups. The multiheaded pyridinium amphiphiles were more active as compared to their 
trimethylammonium counterparts (176). Woude et al. reported that alkyl pyridinium 
cationic lipid (SAINT-2) could increase the membrane permeability although this effect 
is not high to assure the lower cytotoxicity compared to DOTMA (31). Tucker et al. 
reported that pre-incubation of the sponge toxin (a kind of alkyl pyridinium compound) 
with cells could make a transit perforation on the cytoplasm membrane and facilitate 
cDNA transmembrane movement (177). The permeabilization of pyridinium cationic 
lipids was further proved by the evidence of the more efficient tissue penetration of 
pyridinium-based lipoplexes compared to lipoplexes formed by DOTAP in vivo (165). 
The pore on the surface of cell membrane evoked increases in intracellular Ca2+, 
collapsed membrane potentials and reduced input resistance (177,178). DOSPA is a 
polycation which is the component of Lipofectamine. It was reported that polycation 
could form positively charged loops fixed on DNA molecules. These loops interact with 
negatively charged lipids on plasma membranes, which probably induce effective non-
specific endocytosis and subsequent cell transformation (179). Pore-forming ability 
combined with ionic attraction, membrane association and endocytosis, may explain why 
some of our newly synthesized pyridinium cationic lipids showed relatively higher 
transfection efficiency compared to Lipofectamine and Lipofectamine 2000. 
 
In conclusion, we have demonstrated that a number of structural and formulation 
parameters including hydrophobic carbon chain lengths, double bond configuration in the 
unsaturated aliphatic hydrocarbon tails, cationic lipid/co-lipid ratios, cationic lipid/DNA 
charge ratios and cell types play important roles in gene transfer and cytotoxicity of these 
pyridinium lipids. Important findings include: (a) higher transfection efficiencies of 
pyridinium lipids with the amide linkers compared to their ester counterparts; (b) higher 
transfection efficiency at 1:1 molar ratio of pyridinium lipid and co-lipid compared to 2:1 
and 4:1; (c) efficient transfection with C16 chain length pyridinium lipids; (d) better 
transfection efficiencies in the presence and absence of serum, compared to that of 
Lipofectamine, a widely used commercially available liposomal transfection kit; (e) 
higher transfection efficiencies of pyridinium lipids with the trans orientation in the 
hydrophobic anchor chain compared to those with cis orientation; (f) C16:1 trans-isomer 
pyridinium lipids were more efficient in transfection efficiency in the presence of high 
concentration of serum compared with Lipofectamine when lipoplexes were prepared at 
3/1 (+/-) charge ratio; and (g) pyridinium lipids could efficiently deliver siRNAs and 
showed good gene silencing effect. 
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CHAPTER 4. SITE-SPECIFIC DELIVERY OF OLIGONULCLEOTIDES TO 
HEPATOCYTES AFTER SYSTEMIC ADMINSTRATION* 
 
 
4.1 INTRODUCTION 
 
Oligonucleotides (ODNs) have attracted much attention as a new class of 
therapeutic agents that can be used for gene modulation. However, in vivo gene silencing 
by ODNs has not yet been successful because of several obstacles, including the 
nonspecific interaction with plasma proteins, wide distribution and poor stability against 
enzymatic degradation. Since phosphodiester ODNs have extremely short half-lives due 
to degradation by nucleases, phosphorothioate (PS) ODNs are commonly used. PS ODNs 
are fairly stable in vivo, but readily bind to serum proteins, leading to undesirable 
biological events. To address these problems, a variety of delivery systems composed of 
cationic lipids (12,45,180) and cationic polymers (181-183) have been developed. Some 
of these delivery systems substantially enhanced the enzymatic stability and uptake into 
the target cells in vitro (184). However, most of these cationic carriers are inefficient in 
vivo because of their non-specific biodistribution in the body. 
 
We and others have shown that ODNs are cleared rapidly from the circulation and 
accumulated to most of the peripheral tissues, with the highest accumulation in the liver 
and kidney (12,185-188). The asialoglycoprotein receptor is located on parenchymal liver 
cells (e.g., hepatocytes) and recognizes terminal galactose (189) or lactose residues 
(190,191). Therefore, we previously used galactosylated poly(L-lysine) (Gal-PLL) for 
complex formation with ODNs and demonstrated enhanced hepatic uptake of ODNs, 
which was influenced by the particle size, zeta potential, sugar substitution, and 
molecular weight of both polycations and ODNs (192). Although the uptake of Gal-
PLL/ODN complexes by hepatocytes was significantly higher than that of naked ODNs, 
the difference of their distribution to different liver cells was only moderate.  To avoid 
the use of polycations, Rajur et al. (1997) covalently conjugated ODNs to 
asialoorosomucoid via a disulfide bond using sulfosuccinimidyl 6-[3’-(2-pyridyldithio) 
propionamido] hexanoate (sulfo-LC-SPDP), but the authors did not test the conjugate in 
vivo (193). 
 
PEGylation is known to significantly enhance the ODN stability against 
exonucleases and reduce renal clearance compared to unmodified ODNs (194). The in 
vivo activity of a drug depends in part on its rate of excretion and degradation. 
PEGylation should promote the bioactivity of an ODN by increasing plasma residence 
time and decreasing nuclease degradation. PEGylation also shield the inherent negative 
charge of ODN, thereby possibly facilitating cellular uptake of the conjugated drug. 
Additionally, PEGylation could potentially diminish the immunostimulatory effects of  
the ODNs (126). Keeping these benefits in mind, Bonora etal. (1997) conjugated ODNs 
_______________________________ 
* Adapted with permission from American Chemical Society. Zhu, L., Ye, Z., Cheng, K., 
Miller, D. D., and Mahato, R. I. (2008) Site-specific delivery of oligonucleotides to 
hepatocytes after systemic administration. Bioconjug Chem 19, 290-8.  
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to poly(ethylene glycol) (PEG) through a covalent linkage (195). However, these PEG-
ODN conjugates were less effective, since PEG could not be cleaved early from the 
ODNs in the cytoplasm. Therefore, Oishi et al. conjugated ODN to acrylated or 
lactosylated PEG through a pH-responsive ester (139,196). However, these authors did 
not determine the biodistribution of Lac-PEG-ODN and used in conjunction with a 
cationic polymer like linear polyethyleneimine (PEI), which is likely to promote non-
specific interaction with plasmaproteins and uptake by phagocytic cells. 
 
In this study, we used fully phosphorothioate G-rich ODN, which is fairly stable, 
but binds to serum proteins (197). To minimize binding to plasma proteins, enhance 
stability and prolong circulation time, we conjugated Gal-PEG to ODN using an acid 
labile linker. Gal-PEG is expected to enhance ODN delivery to the hepatocytes whose 
inflammation and injury lead to progression of liver fibrosis (198). In this study, we 
conjugated ODN to Gal-PEG via an acid labile ester linkage and used without any 
cationic polymers or lipids to avoid cytotoxicity and non-specific interaction. Following 
conjugation and in vitro characterization, we determined the biodistribution of Gal-PEG-
33P-ODN at whole body, organ (liver) and cellular (liver cells) levels after tail vein 
injection into rats. 
 
 
4.2 MATERIALS AND METHODS 
 
 
4.2.1 Materials 
 
25 mer ODN (5’ GAG GGG GGA GGA GGG AAA GGA AGG G 3’) modified 
with a sulfhydryl group at the 3’-end was purchased from Invitrogen Corporation 
(Carlsbad, CA). [γ-33P]ATP was obtained from MP Biomedicals (Irvine, CA) and T4 
polynucleotide kinase (T4-PNK) from New England Biolabs (Beverly, MA). Bio-Gel P-
6DG gel was purchased from Bio-Rad Laboratories (Hercules, CA). PD-10 desalting 
columns were obtained from Pharmacia Fine Chemicals AB (Uppsala, Sweden). 
Soluene®-350 (tissue solubilizer) and Hionic-Fluor (scintillation fluid) were purchased 
from Perkin Elmer (Boston, MA). Isoflurane was obtained from Baxter Health 
Corporation (Deerfield, IL). Type IV collagenase was purchased from Worthington 
Biochemical Corporation (Lakewood, NJ). NycodenzTM AG was obtained from Greiner 
Bio-One Inc. (Longwood, FL). PE-60 polyethylene tube was purchased from Becton 
Dickinson and Company (Sparks, MD) and heparin solution was procured from 
American Pharmaceutical Partners, Inc. (Los Angeles, CA). Acrylate-PEG-NHS (MW: 
3486±500 Da) was purchased from Nektar Therapeutics (Huntsville, AL). Bovine serum 
albumin (BSA) (fraction V, purity > 98%) was purchased from USB Corporation 
(Cleveland, OH). Palladium (10 wt % on activated carbon), thiophosgene, Brilliant Blue 
R Staining Solution, dithiothreitol (DTT), p-nitrophenyl β-D-galactopyranoside, 
Dimethylformamide (DMF), 2,5-Dihydroxy benzoic acid (DHB), methylene blue, 
deuterium oxide (D2O), triethylamine (TEA, HPLC grade), and pronase were purchased 
from Sigma-Aldrich Chemicals Limited (St. Louis, MO). Dialysis tubing (MWCO 1000 
Da) was purchased from Spectrum Laboratories, Inc. (Houston, TX). Amicon Centricon 
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filter devices (MWCO 10000 Da) were purchased from Millipore Corporation. (Billerica, 
MA). Hydrogen peroxide (H2O2), acetic acid, acetonitrile (ACN, HPLC grade) and water 
(HPLC grade) were purchased from Fisher Chemical (Fair Lawn, NJ). Ca2+/Mg2+-free 
Hank’s balanced salt solution (Cellgro) was purchased from Media Tech (Washington, 
DC). 
 
 
4.2.2 Animals 
 
Male Sprague-Dawley rats weighing 140-160 g were purchased from Harlan Co. 
(San Diego, CA) and were housed individually under the controlled light (12/12 h) and 
temperature conditions and had free access to food and water. 
 
 
4.2.3 Synthesis of Gal-PEG-ODN Conjugate 
 
p-Nitrophenyl β-D-galactopyranoside (200 mg) was reduced with 200 mg of 10% 
palladium on activated carbon under hydrogen (1 atm) in 30 mL of a 1:1 (v/v) ethanol-
water mixture for 2 h, as described by Monsigny et al. (199). The product, p-
aminophenyl β-D-galactopyranoside, was concentrated by solvent removal under vacuum 
and characterized using 1H NMR and mass spectrometry after dissolving in D2O, and the 
NMR spectra were recorded on a Bruker ARX-300 MHz spectrometer at 25 ºC. Chemical 
shifts were recorded in ppm relative to D2O (δ 4.79, 1H). Electron spray ionization (ESI) 
mass spectra were obtained after dissolving the product in methanol on an ESQUIRE-LC 
Ion Trap LC/MS system. Acrylate polyethylene glycol N-hydroxysuccinimidyl (NHS) 
ester (acrylate-PEG-NHS) (58 mg) and p-aminophenyl β-D-galactopyranoside (43.4 mg) 
were dissolved separately in 0.4 mL of DMF, mixed together and stirred for 6 h, then 
dialyzed in 500 mL water for 48 h with MWCO 1000. The product, galactose (Gal)-PEG-
acrylate was characterized by 1H NMR after dissolving the product in D2O. The 
molecular weight of Gal-PEG-ODN was determined using Matrix Assisted Laser 
Desorption/Ionization Time-of-Flight (MALDI-TOF) mass spectrometry with DHB as a 
matrix. 
 
Modified ODNs were treated with 0.2 M DTT in 0.1M, pH 9.0 glycine buffer 
containing 0.1 M NaCl for 3 h at room temperature to generate a 3’-thiol functional group. 
Excess DTT was removed by extraction with ethyl acetate, and ODN was precipitated by 
adding 2.6 volume of ethanol after addition of sodium acetate (NaOAc) to 0.3M. The 
mixture was kept at -30 ºC overnight and centrifuged at 13000 g for 30 min. The ODN 
with 3’-thiol functional group and Gal-PEG-acrylate were dissolved in 0.4 mL water at a 
molar ratio of 1:100, stirred under nitrogen protection at room temperature for 6 h, and 
then centrifuged the mixture by Amicon Centricon filter device (MWCO 10000 Da) at 2, 
500 g for 30 min. The upper solution of the filter device was collected and lyophilized. 
The formation of Gal-PEG-ODN was verified on 20% native polyacrylamide gel 
electrophoresis at 8 V/cm for 100 min at room temperature, followed by gel staining with 
methylene blue. The reaction mixtures and the purity of intermediate and final products 
were monitored by Reverse Phase-High Performance Liquid Chromatography (RP-
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HPLC), which was carried on a reverse phase C18 column (250 mm × 4.6 mm, Alltech, 
Deerfield, IL) by an HPLC system (Waters, Milford, MA) with detection at 260 nm using 
a gradient of 5%-80% ACN in 0.1M triethylammonium acetate at a flow rate of 1.0 
mL/min at 56 ºC. 
 
 
4.2.4 Synthesis of Galactosylated Albumin 
 
Gal-BSA was synthesized from p-aminophenyl β-D-galactopyranoside and BSA 
(MW 66 kDa) using a modified method described by Sando and Karson (200). After 
conjugation Gal-BSA was purified by PD-10 column and identified by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) followed by staining with 
Brilliant Blue R Staining Solution. The molar ratio of galactose and BSA was about 15. 
Sugar (galactose) content was determined by the resorcinol-sulfuric acid method as 
described by Monsigny et al. (201). 
 
 
4.2.5 Radiolabeling of Oligonucleotides 
 
The 25 mer ODN or Gal-PEG-ODN was labeled by adding γ-33P to the 5’ end 
using [γ-33P] ATP and T4-PNK, using the manufacturer’s protocol. Briefly, 1μg of ODN 
or Gal-PEG-ODN was mixed with 5μl of T4-PNK buffer, 2μL of T4-PNK, and 4 μL of 
[γ-33P] ATP. The reaction mixture was incubated at 37 °C for 60 min, followed by 
incubation at 70 °C for 10 min to stop the reaction. Unincorporated [γ-33P] ATP was 
removed from radiolabeled ODN or Gal-PEG-ODN by size exclusion chromatography 
with Bio-Gel P-6DG gel. Radioactivity was measured on TRI-CARB®2000 liquid 
scintillation analyzer (PACKARD Instrument Company, Meridon, CT). The 
incorporation efficiency of the purified 33P-ODN was determined by trichloroacetic acid 
(TCA) precipitation method and the value was more than 95%. The specific activity of 
33P-ODN was about 5 × 105 ~ 10 × 105 cpm/µg. 
 
 
4.2.6 Dissociation and Stability 
 
To determine whether ODNs can dissociate from Gal-PEG-ODN conjugate after 
endocytosis, this conjugate was incubated at 37 ºC in Tris HCl buffer of pH 5.5 for 1, 2 
and 4 h. In addition we also incubated this conjugate in the rat serum at 37 ºC to 
determine its stability. These samples were then detected by 20% polyacrylamide gel 
electrophoresis and autoradiography. 
 
 
4.2.7 Biodistribution of Gal-PEG-ODN 
 
The animal protocol was approved by the Animal Care and Use Committee 
(ACUC), Department of Comparative Medicine, University of Tennessee Health Science 
Center, Memphis, TN 38163. Male Sprague-Dawley rats weighing 140-160 g were used 
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in this study and 4 rats were used for each time point. Unlabeled and Gal-PEG-33P-ODN 
were mixed in saline to give a final concentration of 1 mg/mL and specific activity of 1 × 
106 cpm/mL. Rats were anesthetized by inhalation of isoflurane and Gal-PEG-33P-ODN 
or 33P-ODN was injected via tail vein at a dose of 0.2 mg/Kg body weight. At 2.5, 5, 15, 
30, 90, 240 and 1440 min post injection, 0.5 mL blood was collected by cardiac puncture 
in heparinized tubes, and urine was collected directly from the bladder using 0.26 gauge 
needle syringe. The animals were then sacrificed and major tissues (liver, kidney, spleen, 
heart, lung and muscle) were collected, washed, blotted dry, weighed and stored at -80 ºC. 
The radioactivity of urine sample was counted directly after adding 10 mL of scintillation 
fluid. Two hundred microliters of plasma and 200 mg of each tissue were incubated with 
2 mL tissue solubilizer for 3 h at 55 °C and overnight at 37 °C in shaker. Four hundred 
microliters of H2O2 was added and incubated at 55 °C for another 30 min. Ten milliliters 
of scintillation fluid was added to each sample and the radioactivity was counted using a 
liquid scintillation counter. 
 
 
4.2.8 Determination of Pharmacokinetic Profiles 
 
Plasma data was analyzed using WinNonlin Professional (version 5.0.1, Pharsight 
Corporation, Mountainview, CA). The Gal-PEG-33P-ODN plasma concentration data 
versus time were fitted using one- and two-compartment models, and pharmacokinetic 
parameters were calculated area under the curve (AUC), Cmax, Tmax and Clearance (CL). 
The data were best fitted to a two compartment model where  
 
tt
t BeAeC
       (Eq. 4-1) 
 
and Ct equals concentration at time t, A and B are the y-axis intercepts, and α and β are 
the hybrid constants for distribution and elimination, respectively. Tissue distribution 
data of Gal-PEG-33P-ODN were analyzed in terms of clearance and tissue uptake rate 
index using biexponential equations as described previously. (12) The change in the 
amount of radioactivity in a tissue with time can be described as follows:  
 
)()(/)( tTKtCCLttdT outin     (Eq. 4-2) 
 
where T(t) (% of dose/g) represents the amount of radioactivity in 1 g of the tissue, C(t) (% 
of dose/mL) is the plasma concentration of radioactivity, CLin (mLh-1g-1) is the tissue 
uptake rate index from the plasma to the tissue, and Kout (h-1) is the rate constant for  
efflux from the tissue. In the present study, the efflux process can be considered 
negligible during the initial time points up to 90 min. Hence, eq 1 integrates to  
 
1
1
01
t
0 11
/)()()( tin AUCtTdttCtTCL      (Eq. 4-3) 
 
where t1 (h) is the sampling time. According to Eq. 4-2, the tissue uptake rate index is 
calculated using the amount of radioactivity in the tissue and the area under the plasma 
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concentration-time curve (AUC). Then, the organ clearance (CLorg) is expressed as 
follows: 
 
WCLCL inorg      (Eq. 4-4) 
 
where W (g) is the total weight of the organ. When the tissue uptake process followed 
nonlinear kinetics, CLin values would represent an average value for the overall 
experimental period. Total body clearance (CLtotal) was calculated from AUC for infinite 
time (AUC∞) by the following equation: 
 
 AUCdoseCLtotal /    (Eq. 4-5) 
 
The tissue uptake clearance and index were calculated using the values up to 30 min after 
injection, assuming that ODNs were fairly stable within this period. 
 
 
4.2.9 Competition in Hepatic Uptake of Gal-PEG-ODN 
 
Two minutes before the injection of Gal-PEG-33P-ODN at a dose of 0.2 mg/kg 
(specific activity: 1 × 106 cpm/mL), rats received 10 mg/Kg of Gal-BSA via tail vein 
injection. At 30 min post injection, blood and urine were collected; other major organs 
were harvested as described above for radioactive measurement. 
 
 
4.2.10 Hepatic Cellular Distribution of Gal-PEG-ODN  
 
To determine the effect of conjugation with Gal-PEG on the hepatic uptake of 
ODNs, the liver was isolated and perfused in situ with Ca2+/Mg2+-free Hanks’ balanced  
salt solution containing 0.1% pronase and 0.05% collagenase at 30 min post intravenous 
injection of 33P-ODN or Gal-PEG-33P-ODN into rats as described previously (197). 
Briefly, rats (200-250g) were anesthetized by inhalation of isoflurane, and 100 IU of 
heparin was injected via tail vein, the abdomen was opened, and the portal vein was 
cannulated with PE-60 polyethylene tube. The liver was pre-perfused with 2 mL diluted 
heparin solution, then with 200 mL Ca2+/Mg2+-free Hank’s balanced salt solution and 
finally with Hank’s balanced salt solution containing 0.05% type IV collagenase and  
0.1% pronase for additional 250 mL. All the perfusion solutions were incubated at 37 °C. 
After perfusion, different liver cell types were separated by Nycodenz gradient (202) and 
radioactivity was measured. The contributions of various cell types to the total liver 
uptake were calculated as percentage of total hepatic uptake. 
 
 
4.2.11 Statistical Analysis 
 
Data were expressed as the mean ± standard deviation (SD). The difference 
between any two groups was determined by ANOVA. P < 0.05 was considered 
statistically significant. 
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4.3 RESULTS 
 
Chronic injury and inflammation of hepatocytes often lead to liver fibrosis and 
loss of sinusoidal fenestrae, suggesting that liposomal and nanoparticulate delivery 
systems may not be good for ODN delivery to the hepatocytes. Therefore, we synthesized 
Gal-PEG and conjugated to ODN by β–thiopropionate, an acid-labile linkage which is 
easily cleaved at acidic pH, leading to endosomal release of ODNs after endocytosis 
(196). Following synthesis and characterization, we determined the biodistribution at 
whole body, organ (liver) and cellular (liver cells) levels after systemic administration of 
Gal-PEG-33P-ODN in rats. 
 
 
4.3.1 Synthesis and Characterization of Gal-PEG and Gal-PEG-ODN 
 
The synthesis scheme of Gal-PEG-ODN conjugate is shown in Figure 4.1. p-
Nitrophenyl β-D-galactopyranoside was reduced to p-aminophenyl β-D-
galactopyranoside. ESI-MS and 1H NMR results of this intermediate product are shown 
in Figure 4.2. ESI-MS (positive ion mode): 294.1 ([M + Na]+) (Figure 4.2A); 1H NMR 
(D2O): δ 6.73 (d, 1H), 6.90 (d, 1H), 5.35 (s, 1H), 3.76-4.09 (m, 4H), 3.61 (m, 2H) (Figure 
4.2B). Gal-PEG-acrylate was synthesized from NHS-PEG-acrylate and identified by 
MALDI-TOF MS and 1H NMR. For MALDI-TOF MS, DHB was used as a matrix at the 
weight ratio of 1:2 (Gal-PEG-acrylate/DHB). Molecular weight of Gal-PEG-acrylate was 
3758 Da after conjugation between acrylate-PEG-NHS (MW 3486 Da) and p-
aminophenyl β-D-galactopyranoside (MW 271 Da) (Figure 4.3A). 1H NMR (D2O): δ 
7.35 (d, 2H), 7.12 (d, 2H), 5.54 (s, 1H), 3.48-3.92 (m, 538H), 5.93 (d, 2H), 6.17 (t, 1H), 
6.40 (d, 1H) (Figure 4.3B). Gal-PEG was then conjugated to ODN by Michael addition 
from p-aminophenyl β-D-galactopyranoside and Gal-PEG-acrylate. Gal-PEG-ODN was 
also identified by native polyacrylamide gel electrophoresis (PAGE) and staining with 
methylene blue (Figure 4.4). For the purification process, the RP-HPLC was used to 
monitor the mixtures and the purity of the intermediate and final products. From the 
HPLC chromatograms of ODNs, PEG and Gal-PEG-ODN conjugate shown in Figure 4.5, 
almost all PEG and ODNs were removed from the conjugate after purification. G-rich 
ODNs used in this study has the tendency to form G-quartets, which may decrease the 
recovery of the conjugate. 
 
 
4.3.2 Dissociation and Stability  
 
To determine the dissociation and stability of Gal-PEG-33P-ODN, the 
radioactivity of the samples was measured after gel electrophoresis and autoradiography 
at 0, 1, 2 and 4 h post-incubation of the conjugate in Tris HCl buffer of pH 5.5 and rat 
serum, respectively. In the pH 5.5 buffer, the band of Gal-PEG-33P-ODN gradually 
disappeared along the incubation time, while the band of the 33P-ODN was still there 
even up to 4 h (Figure 4.6). In contrast, this conjugate was fairly stable in rat serum for at  
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Figure 4.1 Synthesis scheme of Gal-PEG-ODN.  
p-Nitrophenyl β-D-galactopyranoside was reduced to p-aminophenyl β-D-
galactopyranoside, which was reacted with easy going group, NHS, of acrylate-PEG-
NHS, resulted in Gal-PEG-acrylate. Then Gal-PEG-acrylate was conjugated to 3’-thiol 
ODN by Michael addition. 
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Figure 4.2 Characterization of p-aminophenyl β-D-galactopyranoside with ESI-
MS and 1H NMR.  
Electron spray ionization mass spectra (A) were obtained after dissolving the product in 
methanol on an ESQUIRE-LC Ion Trap LC/MS system. For 1H NMR (B), samples were 
dissolved in D2O and the spectra were recorded on a Bruker ARX-300 MHz NMR 
spectrometer at 25 ºC. 
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Figure 4.3 Characterization of Gal-PEG-acrylate with MALDI-TOF-MS and 1H 
NMR.  
For MALDI-TOF-MS (A) the ratio between Gal-PEG-acrylate and DHB was 1:2. The 
spectrum was recorded on Voyager-DE RP (PerSeptive Biosystems Inc., MA). For 1H 
NMR (B), samples were dissolved in D2O and the spectra were recorded on a Bruker 
ARX-300 MHz NMR spectrophotometer at 25 ºC. 
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Figure 4.4 Identification of Gal-PEG-ODN by PAGE.  
The gel was running at 80 v for 100 min, followed by staining with methylene blue for 
one night. Lane 1 and 6: ODN 2 μg; lane 2 and 3: Gal-PEG-ODN 2 μg; lane 4 and 5:  
Gal-PEG-ODN 1 μg. 
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Figure 4.5 HPLC chromatograms of ODN (A), PEG (B), reaction mixture (C), 
during purification (D) and after purification (E) of Gal-PEG-ODN. 
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Figure 4.6 Dissociation and stability study of Gal-PEG-33P-ODN.  
Dissociation of 33P-ODN from Gal-PEG-33P-ODN was determined by incubating the 
conjugate at 37 ºC in pH 5.5 buffer, while its stability was determined by incubating the 
conjugate at 37 ºC in rat serum. The band for Gal-PEG-33P-ODN decrease with time 
when incubate at acidic pH. 
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least 4 h. The result suggests that the conjugate was fairly stable in serum, but its acid 
labile ester linkage can be cleaved at acidic pH. Our study also confirmed the previous 
report about this kind of conjugates by Oishi et al. (196). 
 
 
4.3.3 Biodistribution of Gal-PEG-ODN Conjugate 
 
Following synthesis and purification of Gal-PEG and then conjugation to 33P-
ODN, we determined the biodistribution of Gal-PEG-33P-ODN at 2.5, 5, 15, 30, 90, 240 
and 1440 min post injection into the tail vein of rats. Figure 4.7A shows the time course 
of radioactivity in the plasma, urine, liver, kidney, lung, heart and spleen (radioactivity in 
muscle was too low, not shown here). Gal-PEG-33P-ODN was rapidly cleared from the 
circulation with less than 10% of radioactivity detected in the plasma at 30 min post-
injection. Correspondingly hepatic uptake of Gal-PEG-33P-ODN increased with time and 
reached its peak at 30 min post administration and then decreased with time. To compare 
the biodistribution profiles of Gal-PEG-33P-ODN, 33P-ODN was also injected into rats, 
and ODN accumulation and concentration in different organs were determined at 30min 
post-injection. Figure 4.7B shows the tissue concentration of Gal-PEG-33P-ODN in the 
plasma (μg/mL) and tissues (μg/g) after tail vein injection into rats, while the conjugation 
of ODN with Gal-PEG significantly increased the accumulation of radioactivity (% of 
dose) in the liver, as compared to that of 33P-ODN. Gal-PEG-33P-ODN concentration was 
high not only in the liver, but also in the spleen and kidney (Figure 4.7). Almost 60.2% 
(about 2.88 μg ODN/g liver tissue) of the conjugate accumulated in the liver compared to 
about 40% (data not shown) (about 2.01 μg ODN/g liver tissue) accumulation by free 
ODNs at 30 min post administration. Plasma elimination of Gal-PEG-33P-ODN was 
biphasic with a distribution half-life (t1/2α) of 4.38 ± 0.36 min and elimination half-life 
(t1/2β) of 118.61 ± 22.06 min. Figure 4.8 summarized the pharmacokinetic parameters 
such as AUC, Vd, CL and MRT. Consistent with rapid clearance (0.37 ± 0.09 mL/min), 
Gal-PEG-33P-ODN had a large Vd of 35.98 ± 2.64 mL. Table 4.1 summarizes the AUC, 
tissue uptake rate index and organ clearance for representative organs after systemic 
administration of 33P-ODN and Gal-PEG-33P-ODN in rats. The liver uptake rate index 
and clearance of Gal-PEG-33P-ODN were significantly higher than those of 33P-ODN: 
2663.27 ± 56.63 versus 376.15 ± 38.34 µL·h-1·g-1 and 16674.22 ± 354.55 versus 2218.09 
± 205.68 µL·h-1·g-1, respectively. The spleen was in the second place with the tissue 
uptake rate index of 969.26 ± 51.79 versus 204.73 ± 9.64 µL·h-1·g-1 and CLorg of 395.84 ± 
21.15 versus 82.85 ± 7.32 µL·h-1. The tissue uptake rate indices and organ clearances of 
heart, kidney and lung were significantly higher than those of 33P-ODN, possibly due to 
increased in vivo stability of ODN upon conjugation with Gal-PEG. 
 
 
4.3.4 Competition in Hepatic Uptake of Gal-PEG-33P-ODN 
 
The role of asialoglycoprotein receptor on biodistribution of Gal-PEG-33P-ODN 
in rats was assessed by determining the effect of excess Gal-BSA on the accumulation of 
Gal-PEG-33P-ODN in the liver. Galactosylated proteins or polymeric systems are known 
to be taken up by asialoglycoprotein receptor-mediated endocytosis. We have previously  
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Figure 4.7  Accumulation (A) and concentration (B) of Gal-PEG-33P-ODN after 
tail vein injection into rats at a dose of 0.2 mg ODN/Kg of body weight.  
To compare the biodistribution profiles of Gal-PEG-33P-ODN, 33P-ODN was also 
injected, and ODN accumulation and concentration in different tissues were determined 
at 30 min post-injection. Following blood collection by cardiac puncture and urine 
collection from the bladder, the tissues were isolated, digested and subjected to 
radioactivity measurement. The amounts of Gal-PEG-33P-ODN and 33P-ODN were 
converted from there radioactivity, 1 × 106 cpm/mg. Results are presented as the mean ± 
S.D. (n = 4). 
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Figure 4.8 Plasma data was analyzed using a two compartment model with 
WinNonlin Professional (version 5.0.1) software.  
The amount of Gal-PEG-33P-ODN was converted from its radioactivity, 1 × 106 cpm/mg. 
Data are represented as the mean ± SD (n = 4). 
 
PK Parameter Units Estimate
AUC µg·min/ml 84.50±21.59
T1/2α min 4.38±0.36
T1/2β min 118.61±22.06
CL ml/min 0.37±0.09
Vd (ml) 35.98±2.64
MRT min 159.04±31.42
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Table 4.1 Tissue uptake rate index and clearance of 33P-ODN and Gal-PEG-33P-ODN after systemic administration into 
rats. 
 
Samples AUC* (µg·min/mL) 
Tissue uptake rate index (µL·h-1·g-1) Organ clearance (µL·h-1) 
Liver Kidney Heart Spleen Lung Liver Kidney Heart Spleen Lung 
33P-
ODN 
95.15 
±5.11 
376.15 
±38.34 
235.23 
±29.39 
48.76 
±3.42 
204.73 
±9.64 
55.28 
±8.90 
2218.09 
±205.68 
241.00 
±41.08 
22.96 
±1.94 
82.85 
±7.32 
42.21 
±8.44 
Gal-
PEG-
33P-
ODN 
84.50 
±21.59 
2663.27 
±56.63 
376.52 
±11.16 
119.24 
±10.81 
969.26 
±51.79 
161.16 
±7.00 
16674.22 
±354.55 
428.81 
±12.71 
59.67 
±5.41 
395.84 
±21.15 
131.22 
±5.70 
 
* The amount of Gal-PEG-33P-ODN was converted from its radioactivity, 1 × 106 cpm/mg. 
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demonstrated that one minute pre-injection of excess Gal-BSA can saturate 
asialoglycoprotein receptors present on the surface of hepatocytes, resulting in decreased 
hepatic uptake of Gal-PLL/ODN complexes. Staud et al. (1999) also injected 
galactosylated superoxide dismutase (Gal-SOD) two minute post-injection of excess Gal-
BSA and demonstrated significant decrease in the hepatic uptake of Gal-SOD (189). 
Therefore, 2 min interval between the intravenous injections of Gal-BSA and Gal-PEG-
ODN is reasonable for the competition study. Systemic administration of excess Gal-
BSA is known to saturate the asialoglycoprotein receptor of the Hepatocytes (203). Prior 
administration of Gal-BSA at a dose of 10 mg/Kg caused a significant decrease in the 
hepatic uptake of Gal-PEG-33P-ODN, but increase in the radioactivity in plasma and 
other organs at 30 min post injection. The hepatic uptake of Gal-PEG-33P-ODN 
decreased from 60.2% to 35.9% (Figure 4.9). This suggests the involvement of 
asialoglycoprotein receptor in their hepatic uptake. 
 
 
4.3.5 Hepatic Cellular Localization 
 
To determine the intrahepatic localization of Gal-PEG-33P-ODN and to determine 
whether the uptake of this conjugate by hepatocytes is mediated by asialoglycoprotein 
receptors, the liver was perfused at 30 min post tail vein injection of 33P-ODN or Gal-
PEG-33P-ODN, and different types of liver cells were isolated for determining the amount 
of radioactivity in these cells. As shown in Figure 4.10, the hepatocytes were the major 
site for the uptake of Gal-PEG-33P-ODN. At 30 min about 58% of the total liver recovery 
was in the hepatocytes compared to only 30% for the 33P-ODNs (Figure 4.10). 
Accordingly, the uptake of Gal-PEG-33P-ODN in the liver non-parenchymal cells (NPC) 
was 42% compared to 70% for 33P-ODN. This suggests that a large % of the injected 
Gal- PEG-33P-ODN was taken up by the liver via asialoglycoprotein receptor-mediated 
endocytosis. 
 
 
4.4 DISCUSSION 
 
Systemic delivery of ODNs is promising for treating both genetic and acquired 
diseases. Phosphorothioate (PS) ODNs are by far the most extensively studied, and 
significant progress has been made which resulted in one commercial product (Vitravene) 
as well as several promising clinical trials (204). To enhance the cellular uptake of ODNs 
by HepG2.2.15 cells which are stably transfected with hepatitis B virus (HBV), Wu and 
Wu conjugated asialoorosomucoid to poly(L-lysine) and then formed complex with 21 
mer ODN complementary to a portion of human HBV. There was significant increase in 
ODNs uptake by HepG 2.2.15 cells, and the concentration of Hepatitis B Surface Antigen 
(HBsAg) was 80% lower than controls after 24 h (205). However, these authors did not 
determine the biodistribution of asialooromucoid-PLL/ODN complexes after systemic 
administration in rodents. 
 
We have previously shown that although complex formation with Gal-PLL 
enhances ODN uptake by hepatocytes after systemic administration in mice, the  
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Figure 4.9 Effect of Gal-BSA on biodistribution of Gal-PEG-33P-ODN after 
systemic administration into rats.  
Gal-BSA (10 mg/Kg) was injected intravenously into rats 2 minutes before the injection 
of Gal-PEG-33P-ODN at a dose of 0.2 mg/Kg. At 30 minute post injection, rats were 
sacrificed, major organs were isolated and radioactivity was determined. Data are 
represented as the mean ± SD (n = 4). 
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Figure 4.10 Hepatic cellular localization of 33P-ODN and Gal-PEG-33P-ODN.  
The liver was perfused by collagenase/pronase digestion at 30 min post injection of 33P-
ODN or Gal-PEG-33P-ODN at a dose of 0.2 mg/Kg. Parenchymal and non-parenchymal 
cells were separated and the associated radioactivity was measured. Values are the mean 
± S.D. of 4 rats. 
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difference in the intracellular distribution of Gal-PLL/ODN and ODN was only moderate, 
possibly because of the non-specific ionic interaction due to polycations (12). Therefore, 
in this study, we conjugated ODN to Gal-PEG via an acid labile ester linkage of β-
thiopropionate, which will be cleaved in response to a pH decrease in the endosome. 
Oishi et al. (2003) demonstrated the hydrolysis of β-thiopropionate linkage (ester linkage) 
of the PEG-ODN conjugate at pH 5.5, but not at pH 7.4 even after incubation at 37 ºC for 
24 h (196). 
 
Consistent with our results on Gal-PLL/ODN complexes (12), the plasma kinetic 
disposition of Gal-PEG-33P-ODN was characterized by rapid distribution to most 
peripheral tissues, with the highest disposition in the liver (Figures 4.7A and 4.7B). 
Bioconjugation with Gal-PEG decreased the urinary clearance of ODNs to a great extent 
(12). The liver accumulation of Gal-PEG-33P-ODN, including radioactivity and ODN 
concentration, significantly increased within a short time and reached its peak at 30 min 
post administration. Generally, after the peak time point the accumulation of the 
radioactivity and the concentration should decrease along the time. However, in the 
present study both of them showed slight increase in the hepatic uptake at 240 min and 
then decreased, while in other organs the accumulation and concentration of ODNs 
increased significantly until 24 h. The possible reason for this phenomenon is that after 
endocytosis of Gal-PEG-ODN by the liver cells the β–thiopropionate linkage becomes  
not stable and ODN will be released from conjugate gradually. The degradation reaction 
makes the cell an ODN depot. Then some of ODNs can distribute to all over the body. 
 
We determined the role of the asialoglycoprotein receptors on biodistribution of 
Gal-PEG-33P-ODN in rats by the competition effect of excess Gal-BSA on the hepatic 
uptake of ODNs. There was significant decrease in ODN deposition to the liver, but 
increase in its accumulation to other organs and tissues, suggesting that Gal-PEG-ODN 
was taken up by hepatocytes via the galactose-specific asialoglycoprotein receptor 
mediated endocytosis (Figure 4.9). The higher uptake of ODNs in hepatocytes compared 
with non-parenchymal cells in the cellular distribution (Figure 4.10) and the highest 
accumulation of ODNs in liver compared with other organs in whole body level 
biodistribution after ODN conjugated with Gal-PEG (Figure 4.7) further confirmed this 
result. 
 
In conclusion, in this study we synthesized a Gal-PEG-ODN conjugate for site-
specific delivery to hepatocytes. In contrast to 33P-ODN, Gal-PEG-33P-ODN was 
efficiently taken up by hepatocytes and less efficiently by non-parenchymal cells (Figure 
4.10). Thus, non-ionic Gal-PEG-ODN is a promising delivery system which can be used 
for targeted delivery of ODN or siRNA into hepatocytes to treat various liver diseases 
associated with hepatocyte injury and inflammation. 
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CHAPTER 5. TARGETED DELIVERY OF SIRNA TO HEPATOCYTES AND 
HEPATIC STELLATE CELLS 
 
 
5.1 INTRODUCTION 
 
Since they were first discovered, significant progress has been made in enhancing 
the potency and specificity of RNAi molecules. RNAi molecules include double-stranded 
RNA (dsRNA) (2), small interfering RNA (siRNA) (19-23 base-pairs) (4), single 
stranded short hairpin RNA (shRNA) (5) and micro RNA (miRNA) (6). Although they 
are structurally different, all of these molecules induce sequence specific gene silencing 
by either degrading or inhibiting the target mRNA via perfect or mismatched binding in 
the presence of RNA-induced silencing complex (1,2). The simplest and effective 
strategy of gene silencing is to design and synthesize siRNAs based on the target mRNA 
sequence. Most recently, the application of RNAi on the biomedical studies successfully 
demonstrated the potency of synthetic siRNAs as therapeutic agents in the treatment of 
numerous diseases, including cancer, fibrosis, genetic disorders, and viral infection (206-
208). However, siRNAs have not been successfully used as clinical therapeutics due to 
several obstacles, including the poor enzymatic stability, short circulation time in the 
blood stream, non-specific tissue or cell targeting, and insufficient intracellular transport. 
 
A variety of cationic lipids and polymers has been designed as nucleic acid 
delivery carriers. Negatively charged siRNAs could be condensed by cationic lipids or 
polymers via electrostatic interaction to form nano-sized particles which are easy for cells 
to take up via endocytosis, membrane fusion, or both. After complex formation, siRNAs 
are protected from enzymatic digestion (209). However, cationic carriers are not the 
perfect delivery system for in vivo delivery of siRNAs since they may bind to negatively 
charged serum proteins and aggregate together resulting in undesired distribution, and 
induce inflammatory cytokines release and activation of the complement system. 
 
PEGylation is a well known technique which can increase the in vitro and in vivo 
stability of drug molecules as well as improve their pharmacokinetic profiles. In the 
previous study, we reported that conjugation of galactose (Gal)-poly(ethylene glycol) 
(PEG) to oligonucleotide (ODN) using an acid-labile ester linker successfully stabilized 
ODN, prolonged its circulation time, and specifically delivered ODN to hepatocytes 
(134). It was also demonstrated that the cleavable linkage between ODN and PEG could 
be cleaved at pH 5.5 (endosomal pH) and free ODN could be released. We also proved 
that mannose-6-phosphate (M6P) as a ligand could significantly increase accumulation of 
ODN in hepatic stellate cells (HSCs) in rats. Here we used the similar strategy as Gal-
PEG-ODN conjugate to design two siRNA delivery systems, Gal-PEG-siRNA and M6P-
PEG-siRNA. Gal-PEG-siRNA could targeted deliver siRNA to hepatocytes via 
asialoglycoprotein receptor mediated endocytosis, while M6P-PEG-siRNA could 
specifically deliver siRNA to HSCs via M6P/insulin-like growth factor-II receptor 
(M6P/IGF2R) mediated endocytosis. In this study the heterobifunctional PEG, (ortho-
pyridyl) disulfide-poly(ethylene glycol)-N-hydroxysuccinimidyl ester (OPSS-PEG-NHS), 
was used as a backbone followed by modification with either Gal or M6P at its NHS end 
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and with 3’-sense strand of siRNA at its OPSS end via disulfide bond. The conjugates 
were purified by ion exchange HPLC and verified by gel retardation assay. To study the 
gene silencing of siRNA conjugates, the luciferase siRNA was designed and used as the 
model sequence. Finally, the in vitro gene down regulation effects of Gal-PEG-siRNA 
and M6P-PEG-siRNA were evaluated in HepG2 cells and HSCs respectively. 
 
 
5.2 MATERIALS AND METHODS 
 
 
5.2.1 Materials  
 
OPSS-PEG-NHS (MW: 3400 Da) was purchased from Creative PEGWorks 
(Winston Salem, NC). Palladium (10 wt% on activated carbon), thiophosgene, 
dithiothreitol (DTT), L-Glutathione (GSH) reduced, p-aminophenyl β-D-
galactopyranoside, Ethidium Bromide (EtBr), p-nitrophenyl-α-D-mannopyranoside, 
dimethylformamide (DMF), and deuterium oxide (D2O) were purchased from Sigma-
Aldrich Chemicals Limited (St. Louis, MO). Sodium chloride, acetic acid, and HPLC 
grade water were purchased from Fisher Chemical (Fair Lawn, NJ). Luciferase Assay Kit, 
TE buffer, 6 × gel loading buffer, and Tris-hydrochloride were purchased from Promega 
(Madison, WI). Dialysis tubing (MWCO 1000 Da) was purchased from Spectrum 
Laboratories, Inc. (Houston, TX). Zeba Spin Desalting Columns (MWCO: 7000 Da) was 
purchased from Thermo Scientific (Rockford, IL). Dulbecco’s modified Eagle’s medium 
(DMEM), penicillin streptomycin solution (100 ×), Phosphate buffered saline (PBS), 
trypsin-EDTA, Agarose and Lipofectamine 2000 were purchased from Invitrogen 
Corporation (Carlsbad, CA). Bovine serum albumin (BSA) (fraction V, purity > 98%) 
was purchased from Atlanta Biologicals (Lawrenceville, GA). Pyridinium cationic 
liposomes containing pyridinium lipid (C16:1, amide linker, trans)/DOPE (1:1 mol/mol) 
cationic liposomes were prepared by Zhu et al. (30).  
 
 
5.2.2 Small Interfering RNAs (siRNAs) 
 
Luciferase siRNA sequence was obtained from literature (sense strand: 
CUUACGCUGAGUACUUCGA[dT][dT], antisense strand: 
UCGAAGUACUCAGCGUAAG[dT][dT]) and corresponding annealed synthetic siRNA 
was purchased from Invitrogen Corporation. For the conjugation purpose, the sense 
strand of the siRNA was modified with a thiol group (-(CH2)3-S-S-(CH2)3-OH-3’) at its 
3’-end by Invitrogen Corporation. 
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5.2.3 Synthesis of Gal-PEG-siRNA and M6P-PEG-siRNA 
 
5.2.3.1 Synthesis of Ligands (Gal and M6P) 
 
The ligand galactose residue (Gal) was synthesized according to our previous 
study (134). Briefly, p-nitrophenyl β-D-galactopyranoside was reduced with 10% 
palladium on activated carbon under hydrogen (1 atm) in a 1:1 (v/v) ethanol-water 
mixture for 2 h. The product, p-aminophenyl β-D-galactopyranoside, was concentrated 
by solvent evaporation and characterized by 1H NMR and mass spectrometry after 
dissolving in D2O. 
 
The ligand M6P was synthesized according to our previous study (197). Briefly, 
p-nitrophenyl-α-D-mannopyranoside (pnpM) (0.3 g, 1 mmol) was dissolved in 
acetonitrile, pyridine and water mixture (1/0.4/0.04, v/v/v). Phosphorus oxide chloride 
(0.4 mL, 4.4 mmol) was added, and stirred for 1 h on an ice-water bath. The reaction 
mixture was poured onto 20 g of ice. After the ice melted, the pH was adjusted to 7.0 by 
slowly adding 2.5 M NaOH, and the solution was evaporated to dryness. The solid 
material was dissolved in water and crystallized at 4 °C overnight. The crystals were 
filtered and washed with 5 mL of absolute ethanol. The compound was recrystallized in a 
mixture of 1 mL of water and 10 mL of ethanol, redissolved in water, and lyophilized to 
give p-nitrophenyl-6-phospho-α-D-mannopyranoside (pnpM6P). PnpM6P was reduced 
with 100 mg of 10% palladium on activated carbon under H2 (1 atm) in a 4:1 (v/v) 
methanol-water mixture for 2 h. After filtration, the residue was redissolved in water and 
lyophilized to give p-aminophenyl-6-phospho-α-D-mannopyranoside (papM6P). The 
product was characterized using 1H NMR and mass spectrometry. 
 
5.2.3.2 Synthesis of Gal-PEG-OPSS and M6P-PEG-OPSS 
 
OPSS-PEG-NHS (50 mg) and galactose (Gal) (50 mg) were dissolved separately 
in 0.4 mL of DMF, mixed together, and stirring for 6 h at room temperature under N2 
protection in the dark. The reaction mixture was dialyzed against distilled water for 48 h 
with MWCO 1000 to remove the unreacted Gal. The product Gal-PEG-OPSS was freeze 
dried and characterized by 1H NMR after dissolving it in D2O.  
 
OPSS-PEG-NHS (50 mg) were dissolved in 0.4 mL of DMF, and papM6P (50 mg) 
was dissolved in 0.4 distilled water. Then mixed them dramatically, and stirred for 6 h at 
room temperature under N2 protection in the dark. The reaction mixture was dialyzed 
against distilled water for 48 h with MWCO 1000 to remove the unreacted papM6P. The 
product M6P-PEG-OPSS was freeze dried and characterized by 1H NMR after dissolving 
it in D2O. 
 
5.2.3.3 Synthesis of Gal-PEG-siRNA and M6P-PEG-siRNA 
 
The lyophilized 3’ thiol-siRNA was reconstituted in TE buffer (pH 8.3-8.5) at a 
concentration of approximately 100 A260 units/mL. siRNA solution was then treated 
with 0.1 M DTT aqueous solution at room temperature for 30 minutes. The excess DTT 
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was removed by gel filtration and 3’-sulfhydryl siRNA was stored under N2 to avoid 
oxidative dimerization to the disulfide before the conjugation reaction. 3’-sulfhydryl 
siRNA and Gal-PEG-OPSS (or M6P-PEG-OPSS) were dissolved in 0.5 mL PBS (pH7.5) 
at a molar ratio of 1:100, and stirred under nitrogen protection at room temperature for 6 
h. The reaction mixture was analyzed and purified by ion exchange high performance 
liquid chromatography (ion exchange HPLC), which was carried on a Resource Q ion 
exchange column (GE Healthcare Life Sciences, Piscataway, NJ) by an HPLC system 
(Waters, Milford, MA) with detection at 260 nm using a gradient starting from 0% B to 
80% B (A: 20 mM Tris-HCl buffer, B: 0.1 M sodium chloride buffer) at a flow rate of 1 
mL/min at 25 °C. The purified Gal-PEG-siRNA and M6P-PEG-siRNA were desalted 
using Zeba Spin Desalting Column by centrifuge at the speed of 2000 g and dried by 
freeze drier. 
 
5.2.3.4 Characterization of Gal-PEG-OPSS and M6P-PEG-OPSS 
 
The concentration of siRNA and siRNA conjugate solutions were quantitated by 
UV spectrophotometer. For determination of the cleavage of disulfide bond and siRNA 
dissociation from Gal-PEG-siRNA and M6P-PEG-siRNA, 2 μg siRNA and the 
conjugates containing 2 μg siRNA were incubated in 50 mM DTT aqueous buffer for 40 
min at room temperature respectively. The DTT treated samples and controls (non-treated 
siRNA and siRNA conjugate) were mixed with 6 × gel loading buffer and applied on the 
1% agarose gel and run at 10 V/cm for 60 min at room temperature followed by EtBr 
staining and visualization under UV light. 
 
5.2.3.5 Cell Cultures and Transfections 
 
HepG2 cells were maintained in a complete growth medium containing DMEM 
medium supplemented with 10% FBS, 100 IU/mL penicillin, and 100 μg/mL 
streptomycin at 37 °C in a 5% CO2 humidified atmosphere.  HSC-T6 cells, kindly 
provided by Dr. Scott Friedman (Mount Sinai School of Medicine, New York), were 
maintained in the same condition as HepG2 cells. Before transfection, the cells were 
seeded in 24-well plates and maintained in 0.5 mL of complete growth medium at 37 °C 
for 24 h. The cell number was about 4 × 104 cells per well. 
 
Luciferase expression plasmid (pDNA3-Luc) was first transfected with cells by 
pyridinium cationic liposomes. Briefly, 0.4 µg/well luciferase plasmid and pyridinium 
cationic liposomes were diluted to 25 μL by Opti-MEM I medium, respectively, and 
incubated for 5 min at room temperature. Lipoplexes were prepared by mixing plasmid 
and liposomes in equal volume, and incubated for 20 min at room temperature to allow 
complex formation. Immediately before transfection, the media was removed, and cells 
were washed gently with sterile phosphate buffered saline. Lipoplexes were added to 
each well, diluted to 0.5 mL by Opti-MEM I medium, and the plate was incubated under 
5% CO2 at 37 °C for 6 h. Following transfection, the culture medium was replaced with 
complete growth medium and maintained overnight before further treatment. 
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To transfect luciferase siRNA and its conjugate, two methods were used. In the 
method one, siRNAs and its conjugate were added directly into cell cultures without the 
assistance of cationic liposomes. In the method two, siRNA and its conjugate mixed with 
cationic liposomes to form the lipoplexes before adding into cell cultures (the same 
procedure as the transfection of luciferase plasmid). The transfection time of siRNA and 
its conjugate was 6 h. Then the medium was replaced with the complete growth medium 
and incubated for another 42 h. 
 
To determine the luciferase gene expression, the cells were collected and lysed. 
The cell lysate was measured for luciferase gene expression by Luciferase Assay Kit 
(Promega, Madison, WI). The total protein concentration was measured by bicinchoninic 
acid (BCA) protein assay reagent (Pierce, Rockford, IL). Luciferase activity was 
normalized by the total protein content and expressed as relative light unit (RLU) per μg 
of protein (RLU/μg protein). 
 
 
5.3 RESULTS 
 
 
5.3.1 Synthesis of Gal-PEG-siRNA and M6P-PEG-siRNA 
 
The synthesis scheme of Gal-PEG-siRNA and M6P-PEG-siRNA was shown in 
Figure 5.1. Before conjugation reaction, the ligands were synthesized. p-Nitrophenyl β-
D-galactopyranoside was reduced to p-aminophenyl β-D-galactopyranoside. ESI-MS and 
1H NMR results of this intermediate product were not shown and could be found in our 
previous paper (134). p-Nitrophenyl-α-D-mannopyranoside (pnpM) was phosphorylated 
to p-nitrophenyl-6-phospho-α-D-mannopyranoside (pnpM6P) and pnpM6P was reduced 
to p-aminophenyl-6-phospho-α-D-mannopyranoside (papM6P). ESI-MS and 1H NMR 
results of this intermediate product are shown in Figure 5.2. 
 
Gal-PEG-OPSS and M6P-PEG-OPSS were synthesized from heterofunctional 
PEG derivative, NHS-PEG-OPSS and identified by 1H NMR. NHS group is an easygoing 
group which is ready to react with amine group. After reaction with Gal or M6P, the two 
peaks (a and b positions) of the benzene ring were found in the NMR spectrum. The data 
indicated that Gal and M6P reacted with NHS group and linked with PEG (Figure 5.3). 
Gal-PEG-OPSS and M6P-PEG-OPSS were then conjugated to 3’-sulfhydryl siRNA by 
disulfide exchange reaction between sulfhydryl and OPSS groups. For the purification 
process, ion exchange HPLC was used to monitor the conjugation reaction and purify the 
final products. The ion exchange HPLC chromatograms of siRNAs, Gal-PEG-OPSS, 
M6P-PEG-OPSS, Gal-PEG-siRNA and M6P-PEG-siRNA conjugate were shown in 
Figure 5.4. Gal-PEG-OPSS or M6P-PEG-OPSS first eluted since it has no charge and 
could not bind to anion exchange resin; free siRNAs are negatively charged molecules 
and bound to anion exchange resin and eluted last; after conjugation, the charge of 
siRNA was partially blocked by the flexible long chain of PEG and eluted between PEG 
and siRNA. Gal-PEG-siRNA and M6P-PEG-siRNA were also identified by 1% agarose 
gel electrophoresis and visualization under UV light (Figure 5.5).  
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Figure 5.1 Synthesis scheme of Gal-PEG-siRNA and M6P-PEG-siRNA. 
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Figure 5.2 Characterization of p-aminophenyl-6-phospho-α-D-mannopyranoside 
with ESI-MS and 1H NMR.  
Synthesis scheme of p-aminophenyl-6-phospho-α-D-mannopyranoside (A). Electron 
spray ionization mass spectra (B) were obtained after dissolving the product in a 4:1 (v/v) 
methanol-water mixture on an ESQUIRE-LC Ion Trap LC/MS system in negative mode. 
For 1H NMR (C), samples were dissolved in D2O and the spectra were recorded on a 
Bruker ARX-500 MHz NMR spectrometer at 25 ºC. 
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Figure 5.3 Characterization of Gal-PEG-OPSS (A) and M6P-PEG-OPSS (B) 
with 1H NMR.  
The samples were dissolved in D2O and the spectra were recorded on a Bruker ARX-500 
MHz NMR spectrometer at 25 ºC. 
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Figure 5.4 Purification of Gal-PEG-siRNA and M6P-PEG-siRNA by Ion 
Exchange Chromatography.  
The reaction mixture was carried on a ResourceTM Q ion exchange column (GE 
Healthcare Life Sciences, Piscataway, NJ) by an HPLC system (Waters, Milford, MA) 
with detection at 260 nm using a gradient starting from 0% B to 80% B (A: 20 mM Tris-
HCl buffer, B: 0.1 M sodium chloride buffer) at a flow rate of 1 mL/min at 25 °C. 
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Figure 5.5 Identification of siRNA conjugates by gel retardation assay.  
Two micrograms of siRNAs, Gal-PEG-siRNA, and M6P-PEG-siRNA were incubated 
with 50 mM DTT at the room temperature for 40 min. The treated samples and non-
treated controls were applied on 1% agarose gel and run at 10 V/cm for 60 min followed 
by EtBr staining, then visualized under UV light. 
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5.3.2 Dissociation of siRNAs from Gal-PEG-siRNA and M6P-PEG-siRNA 
 
To determine that the disulfide bond between PEG and siRNA was cleavable and 
free siRNA could be released, siRNA and its conjugate were first precisely quantitated by 
nanodrop uv spectrophotometer (Thermo Scientific, Rockford, IL). Then two microgram 
of siRNA, Gal-PEG-siRNA, and M6P-PEG-siRNA were treated with DTT aqueous 
buffer (50 mM) at the room temperature for 40 min and analyzed by gel retardation assay 
which was carried on 1% agarose gel at 10 V/cm for 60 min and visualized under UV 
light. Agarose gel electrophoresis data showed that siRNA conjugate migrate slower than 
free siRNA. And after treatment of DTT for 40min, disulfide bond was completely 
cleaved and free siRNA was released and migrated at the same speed as that of siRNA 
control (Figure 5.5).  
 
 
5.3.3 Gene Down-regulation Study 
 
Exogenous firefly luciferase plasmid was transfected into both HepG2 and HSC 
cells using previously optimized pyridinium cationic liposomes at the charge ratio of 3:1 
(N/P). The transfection efficiency of pyridinium cationic liposomes was well studied by 
Zhu et al.. (30) The gene down-regulation effects of siRNA conjugates were studied after 
transfection of luciferase gene. Figure 5.6A showed the luciferase gene down regulation 
effect of Gal-PEG-siRNA conjugate in HepG2 cells without transfection reagent, 
pyridinium cationic liposomes. Without cationic liposomes, Gal-PEG-siRNA conjugate 
could down-regulate the gene expression of luciferase up to about 45% at the dose of 400 
nM compared to the naked siRNA group and the group (plasmid group) without siRNA 
treatment. Addition of excessive amount of Gal-PEG into HepG2 cells before 
transfection of siRNA conjugate abolished the gene down-regulation effect of Gal-PEG-
siRNA conjugate. Figure 5.6B showed the gene down regulation of luciferase siRNA and 
Gal-PEG-siRNA. After complex formation with pyridinium cationic liposomes, the gene 
silencing effect of Gal-PEG-siRNA significantly increased and reached about 90% even 
at the dose of 100 nM, while the gene silencing effect of luciferase siRNA was just about 
60% at the same dose. Figure 5.6C showed the gene down-regulation effect of M6P-
PEG-siRNA in HSC cells without pyridinium cationic liposomes. M6P-PEG-siRNA 
could down-regulate the luciferase gene expression at the similar level as that of Gal-
PEG-siRNA. Pre-treatment of HSC cells with excessive amount of M6P-PEG before 
transfection of siRNA conjugate abolished the gene down-regulation effect of M6P-PEG-
siRNA conjugate too. The gene down-regulation effect of both Gal-PEG-siRNA and 
M6P-PEG-siRNA was dose dependent in both absence and presence of pyridinium 
cationic liposomes. 
 
 
5.4 DISCUSSION 
 
To effectively deliver siRNA to the specific types of cells in vivo is critical for a 
successful siRNA therapeutic. The current studies of siRNA delivery systems are more 
focused on cationic particulate delivery systems since negatively charged siRNAs  
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Figure 5.6 In vitro gene down regulation effects of Gal-PEG-siRNA and M6P-
PEG-siRNA.  
Before gene silencing study, luciferase plasmid was transfected into both HepG2 and 
HSC cells using lipoplexes formed between luciferase plasmid and pyridinium cationic 
liposomes at the charge ratio of 3/1 (+/-). To study the gene silencing ability of Gal-PEG-
siRNA, luciferas siRNA and its Gal-PEG-siRNA conjugate were added into HepG2 cells 
without (A) and with (B) the formation of siRNA/liposomes complexes using pyridinium 
cationic liposomes. For M6P-PEG-siRNA, luciferas siRNA and its M6P-PEG-siRNA 
conjugate were added directly into HSC cells without cationic liposomes (C). 
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are easily condensed by or incorporated into positively charged liposomal or polymeric 
carriers. These carriers are shown to protect siRNAs from degradation as well as enhance 
siRNAs’ cellular uptake. However, an ideal delivery carrier should be a cation-free 
system since the positive charge may cause the immune response and non expected 
distribution. A lot of non-cationic carriers are designed to deliver nucleic acids. Among 
them, water soluble macromolecular delivery systems are found to be potential since they 
are small and thermodynamically stable, and have less undesired protein binding and 
immune response. 
 
It was reported that nucleic acids are cleared rapidly from blood circulation and 
mostly accumulated in the peripheral tissues, especially in liver and kidney (12,13,186). 
However, the in vivo activity of a therapeutic partly depends on its pharmacokinetic 
behavior, especially the rate of excretion and degradation. PEGylation is known to 
significantly enhance nucleic acids’ stability against exonucleases and reduce renal 
clearance compared to unmodified nucleic acids (194), which may improve the 
bioactivity of nucleic acids by increasing plasma residence time and decreasing nuclease 
degradation. The flexible PEG chains also shield the inherent negative charge of nucleic 
acids, thereby possibly facilitating cellular uptake of the conjugated nucleic acids. 
 
In a previous study we successfully conjugated ODN to Gal-PEG via an acid 
labile linkage and demonstrated that Gal-PEG significantly increased ODNs’ 
accumulation in hepatocytes via galactose-asialoglycoprotein receptor mediated 
endocytosis after systemic administration of Gal-PEG-ODN in rats (134). In another 
study, M6P was also successfully linked to BSA followed by conjugation with ODN. The 
M6P-BSA-ODN conjugate increased the accumulation of ODNs in HSCs via M6P 
ligand-M6P/IGF2R mediated endocytosis compared to other types of liver cells after i.v. 
injection of it in rats (197). In the present study, we investigated the application of PEG 
based macromolecular delivery system using two different ligands for siRNA delivery. 
Since disulfide bond was proven to be cleaved by reducing agents in cytoplasm and was 
extensively used in drug delivery systems (138,141,210,211), here we used cleavable 
disulfide bond as the linkage between siRNA and PEG to ensure intact siRNA molecules 
release from the conjugates in the reducing environment in cytoplasm where RNAi takes 
action after endocytosis. 
 
Liver fibrosis is one of the most difficult cure diseases and has limit number of 
effective therapeutics in the clinics. It is a result of the excessive accumulation of 
extracellular matrix (ECM) proteins in liver and originates from chronic liver injury and 
inflammation of hepatocytes (major cells in liver) or other hepatic cells. In fibrotic liver, 
hepatic stellate cells is activated and transformed to proliferative myofibroblast-like cells, 
which is believed the major source of ECM synthesis. To treat liver fibrosis, design of 
drug delivery system to targeted deliver therapeutic agents to both hepatocytes and HSCs 
can enhance the efficacy and decrease the side effects of drug molecules. Excessive ECM 
causes the loss of sinusoidal fenestrae (212), suggesting that liposomal and other 
particulate delivery systems may not be suitable for siRNA delivery to hepatic cells. 
Compared to particulate delivery systems, the water soluble delivery system, Gal-PEG-
siRNA or M6P-PEG-siRNA, is much more attractive to deliver therapeutics to hepatic 
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cells in fibrotic liver. Firefly luciferase gene was one of the mostly used exogenous 
reporter gene in the biological studies. In present study we first transfected luciferase 
plasmid and allowed luciferase gene expression in both HepG2 and HSC cells. Then the 
gene silencing effects of siRNA conjugates were determined in these luciferase 
expression cells. 
 
Since siRNAs are relatively smaller and easier to be produced and handled than 
plasmids, they are readily modified by other functional molecules directly to improve 
their stability and pharmacokinetic behaviors (134). siRNAs can be covalently linked 
with functional molecules via either non-cleavable or cleavable linkage, such as acid-
labile ester (134,139) and reducible disulfide bond (140,141). For single-stranded 
oligonulceotides, both 3’- and 5’-terminus of these molecules are reported to be used as 
the functional sites for the conjugation reaction (134,142). For siRNA duplex, however, it 
is known that antisense strand of siRNA plays a key role and works as the template in 
RISC to perform RNAi. Improper modification of antisense strand may cause the loss of 
RNAi function (213). It was further shown that 5’-terminus of antisense strand was more 
important than 3’-terminus and determined RNAi activity (143-145). Compared to 
antisense strand, manipulation of sense strand of siRNA is relatively safe and effective. 
Both 3’- and 5’-end of sense strand can be used to make a conjugation (121). 
 
In this study, 3’-thiol modifier, was first reduced to 3’-sulfhydryl group which 
was active and could form a disulfide bond with (ortho-pyridyl) disulfide (OPSS) group 
by disulfide exchange reaction in PBS. The disulfide bond was expected to be cleaved 
and free siRNAs were released after treatment with reducing agent DTT. This was 
confirmed by the result of gel retardation assay that the released siRNAs migrated at the 
same rate as those of unmodified siRNAs after treatment with DTT. This indicated that 
the MW and structure of duplex siRNA molecules probably didn’t change. The luciferase 
gene down-regulation of siRNA conjugates indicated that siRNAs didn’t lose their RNAi 
function during conjugation and after dissociation from siRNA conjugates (Figure 5.6). 
siRNA conjugates just had about 40% down-regulation of luciferase gene at the dose of 
400 nM in both HepG2 and HSCs in the absence of cationic liposomes (Figures 5.6A and 
5.6C), while the luciferase gene was almost completely silenced in the presence of 
cationic liposomes at the same condition (Figure 5.6B). Without condensation with 
cationic liposomes, the flexible hydrophilic PEG chain surrounds and shields siRNA or 
the ligand on it from accessing cell membrane, thereby decreasing both specific and non-
specific endocytosis. After complex formation with cationic liposomes, the lipoplexes 
were slightly positively charged and easy for cells to take up (non-specific) and had high 
gene silencing effects. Furthermore, combination of ligand-receptor mediated specific 
endocytosis, siRNA conjugates showed higher gene silencing effect compared to naked 
siRNAs (Figure 5.6B). However, in the in vivo situation, pegylated siRNAs will be 
retained in blood circulation and cleared very slow compared to naked siRNAs. Our 
previous studies showed that pegylated ODN could significantly prolong the elimination 
half life (t1/2β) of ODN up to 118.61 ± 22.06 min (134) compared to only 34.60 ± 4.32 
min of naked ODN after i.v. injection in rats (197). The longer residence will provide the 
sufficient time for siRNA conjugates to access their target cells and initiate the ligand-
receptor mediated endocytosis. In Figures 5.6A and 5.6C, pre-addition of excessive 
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amount of Gal-PEG or M6P-PEG significantly inhibited gene down-regulation effect of 
corresponding siRNA conjugates, which indicated that the cellular uptake of siRNA 
conjugates was ligand-receptor mediated endocytosis, but not non-specific endocytosis. 
So in vivo we can predict that cation-free Gal-PEG-siRNA and M6P-PEG-siRNA will be 
specifically accumulated in hepatocytes or HSCs and minimize the non specific 
distribution and immunostimulatory effect. 
 
In conclusion, we successfully conjugated siRNA with Gal-PEG-OPSS or M6P-
PEG-OPSS via disulfide bond. The siRNA conjugates were purified and characterized by 
gel retardation assay. The gene silencing effects of Gal-PEG-siRNA and M6P-PEG-
siRNA were observed in HepG2 and HSCs. Gal-PEG-siRNA and M6P-PEG-siRNA may 
be a suitable delivery system for targeted delivery of siRNAs to hepatocytes and HSCs. 
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CHAPTER 6. SUMMARY AND PRESPECTIVES 
 
 
Nucleic acids are unstable macromolecules which are difficult for target cells to 
take up due to biological barriers. In this dissertation we designed the lipid and polymeric 
carriers for in vitro and in vivo nucleic acid delivery. 
 
In Chapter 3, pyridinium lipids which contain a heterocyclic ring and a nitrogen 
atom were synthesized. These pyridinium lipids were characterized by measuring their 
phase transition temperatures and melting points, and corresponding cationic liposomes 
were characterized by their particle sizes and zeta potentials. The structure-activity 
relationship and formulation of corresponding cationic liposomes were studied using 
luciferase and GFP plasmid as reporter genes in CHO cells. Based on these studies, we 
found the best formulation (C16:1 trans-isomer and DOPE) and verified it in 
hepatocarcinoma and prostate cancer cells. The optimized formulation was further 
investigated in the delivery of siRNAs and showed higher gene silencing effect at the low 
dose of siRNAs compared to Lipofectamine 2000. 
 
To design an in vivo delivery system, in Chapter 4 we successfully synthesized a 
non-cationic water soluble macromolecular delivery system Gal-PEG-ODN via an acid-
labile ester linkage of β-thiopropionate. The conjugate was purified by RP-HPLC and 
verified by polyacrylamide gel electrophoresis. PEGylation of ODN significantly 
increased its circulation time and protected ODN from enzymatic digestion. ODN was 
dissociated from Gal-PEG-ODN at low pH. The biodistribution, competition and hepatic 
cellular localization data showed that Gal-PEG-ODN could targeted deliver its payload to 
hepatocytes after i.v. injection. 
 
Use the similar strategy of Gal-PEG-ODN, in Chapter 5 we designed PEG based 
siRNA conjugates, Gal-PEG-siRNA and M6P-PEG-siRNA. After conjugation reaction, 
the conjugate was purified by ion exchange HPLC and verified by agarose gel 
electrophoresis. Disulfide bond between PEG and siRNA could be cleaved by DTT, 
thereafter intact siRNA was released. To evaluate their RNAi functions, an effective 
luciferase siRNA sequence was designed and conjugated with Gal-PEG and M6P-PEG. 
Both conjugates could down-regulate luciferase gene expression for about 40% without 
any transfection reagents, while the gene down-regulation level reached more than 98% 
with the help of cationic liposomes at the same dose. 
 
In conclusion, we synthesized a series of pyridinium lipids and studied their SAR 
and corresponding liposomal formulations. We found pyridinium lipids showed high 
transfection efficiency and have the potential to be used as transfection reagents in vitro. 
However, to make them more effective and less toxic especially in vivo, the more 
structures should be studied including different fatty acid chains (such as branched chain 
or more double bonds), different type of hydrophobic groups (such as cholesterol), and 
different linkers (such as ether and carbamate). Pyridinium lipids should be also modified 
by polymers or peptides to enhance their transfection efficiencies and decrease their side 
effects. For in vivo delivery of nucleic acids, since positive surface charge prompt non-
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specific ionic interaction with plasma proteins and other tissues, leading to complement 
system activation or toxicity, PEGylation can block the positive charge of cationic 
liposomes and decrease the non-specific distribution and unexpected immune response. 
For specific delivery of nucleic acids, we have demonstrated that the non-cationic 
polymeric conjugates, Gal-PEG-ODN, Gal-PEG-siRNA and M6P-PEG-siRNA, could 
targeted deliver nucleic acids to hepatic cells. They are more suitable for in vivo delivery 
of nucleic acids because of their long circulation time and enhanced targeting efficiency. 
However, in our studies, only the reporter genes were targeted, which is not sufficient to 
evaluate the nucleic acid delivery systems. In the future, the therapeutic genes will be 
used as the target genes to test these delivery systems. In short, the research in this 
dissertation strengthened the development of lipid and polymeric carriers as the effective 
nucleic acid delivery systems. 
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